

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Form 10-Q**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934**

For the quarterly period ended June 30, 2016

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number 000-30833

**BRUKER CORPORATION**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**04-3110160**  
(I.R.S. Employer  
Identification No.)

**40 Manning Road, Billerica, MA 01821**  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(978) 663-3660**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☒

Accelerated filer ☐

Non-accelerated filer ☐

Smaller reporting company ☐

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

| Class                                    | Outstanding at August 1, 2016 |
|------------------------------------------|-------------------------------|
| Common Stock, \$0.01 par value per share | 161,527,691 shares            |

---

---

**B RUKER CORPORATION**

**Quarterly Report on Form 10-Q  
For the Quarter Ended June 30, 2016**

**Index**

|                                                                                                                                                          | <b>Page</b> |
|----------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| <b><u>Part I</u></b>                                                                                                                                     |             |
| <b><u>FINANCIAL INFORMATION</u></b>                                                                                                                      |             |
| <u>Item 1:</u>                                                                                                                                           |             |
| <a href="#">Unaudited Condensed Consolidated Financial Statements</a>                                                                                    | 1           |
| <a href="#">Unaudited Condensed Consolidated Balance Sheets as of June 30, 2016 and December 31, 2015</a>                                                | 1           |
| <a href="#">Unaudited Condensed Consolidated Statements of Income and Comprehensive Income for the three and six months ended June 30, 2016 and 2015</a> | 2           |
| <a href="#">Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2016 and 2015</a>                                | 3           |
| <a href="#">Notes to Unaudited Condensed Consolidated Financial Statements</a>                                                                           | 4           |
| <u>Item 2:</u>                                                                                                                                           |             |
| <a href="#">Management’s Discussion and Analysis of Financial Condition and Results of Operations</a>                                                    | 19          |
| <u>Item 3:</u>                                                                                                                                           |             |
| <a href="#">Quantitative and Qualitative Disclosures About Market Risk</a>                                                                               | 35          |
| <u>Item 4:</u>                                                                                                                                           |             |
| <a href="#">Controls and Procedures</a>                                                                                                                  | 37          |
| <b><u>Part II</u></b>                                                                                                                                    |             |
| <b><u>OTHER INFORMATION</u></b>                                                                                                                          |             |
| <u>Item 1:</u>                                                                                                                                           |             |
| <a href="#">Legal Proceedings</a>                                                                                                                        | 37          |
| <u>Item 1A:</u>                                                                                                                                          |             |
| <a href="#">Risk Factors</a>                                                                                                                             | 37          |
| <u>Item 2:</u>                                                                                                                                           |             |
| <a href="#">Unregistered Sales of Equity Securities and Use of Proceeds</a>                                                                              | 37          |
| <u>Item 3:</u>                                                                                                                                           |             |
| <a href="#">Defaults Upon Senior Securities</a>                                                                                                          | 38          |
| <u>Item 4:</u>                                                                                                                                           |             |
| <a href="#">Mine Safety Disclosure</a>                                                                                                                   | 38          |
| <u>Item 5:</u>                                                                                                                                           |             |
| <a href="#">Other Information</a>                                                                                                                        | 38          |
| <u>Item 6:</u>                                                                                                                                           |             |
| <a href="#">Exhibits</a>                                                                                                                                 | 38          |
| <a href="#">Signatures</a>                                                                                                                               | 39          |

---

**PART I FINANCIAL INFORMATION**
**ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**BRUKER CORPORATION**  
**UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS**  
(in millions, except share and per share data)

|                                                                                                                                                                                                                 | June 30,<br>2016  | December 31,<br>2015 |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|----------------------|
| <b>ASSETS</b>                                                                                                                                                                                                   |                   |                      |
| Current assets:                                                                                                                                                                                                 |                   |                      |
| Cash and cash equivalents                                                                                                                                                                                       | \$ 232.5          | \$ 267.1             |
| Short-term investments                                                                                                                                                                                          | 187.9             | 201.2                |
| Accounts receivable, net                                                                                                                                                                                        | 206.9             | 234.7                |
| Inventories                                                                                                                                                                                                     | 471.0             | 422.0                |
| Other current assets                                                                                                                                                                                            | 117.1             | 106.5                |
| Total current assets                                                                                                                                                                                            | 1,215.4           | 1,231.5              |
| Property, plant and equipment, net                                                                                                                                                                              | 236.8             | 231.1                |
| Intangibles, net and other long-term assets                                                                                                                                                                     | 268.3             | 267.4                |
| Total assets                                                                                                                                                                                                    | <u>\$ 1,720.5</u> | <u>\$ 1,730.0</u>    |
| <b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>                                                                                                                                                                     |                   |                      |
| Current liabilities:                                                                                                                                                                                            |                   |                      |
| Current portion of long-term debt                                                                                                                                                                               | \$ 20.3           | \$ 0.6               |
| Accounts payable                                                                                                                                                                                                | 88.0              | 72.1                 |
| Customer advances                                                                                                                                                                                               | 153.9             | 178.3                |
| Other current liabilities                                                                                                                                                                                       | 272.9             | 303.5                |
| Total current liabilities                                                                                                                                                                                       | 535.1             | 554.5                |
| Long-term debt                                                                                                                                                                                                  | 322.7             | 265.2                |
| Other long-term liabilities                                                                                                                                                                                     | 192.3             | 177.4                |
| Commitments and contingencies (Note 10)                                                                                                                                                                         |                   |                      |
| Shareholders' equity:                                                                                                                                                                                           |                   |                      |
| Preferred stock, \$0.01 par value 5,000,000 shares authorized, none issued or outstanding                                                                                                                       | —                 | —                    |
| Common stock, \$0.01 par value 260,000,000 shares authorized, 170,381,491 and 169,644,644 shares issued and 161,509,041 and 165,354,180 shares outstanding at June 30, 2016 and December 31, 2015, respectively | 1.7               | 1.7                  |
| Treasury stock, at cost, 8,872,450 and 4,290,527 shares at June 30, 2016 and December 31, 2015, respectively                                                                                                    | (208.7)           | (90.9)               |
| Accumulated other comprehensive loss                                                                                                                                                                            | (28.7)            | (44.2)               |
| Other shareholders' equity                                                                                                                                                                                      | 899.0             | 859.5                |
| Total shareholders' equity attributable to Bruker Corporation                                                                                                                                                   | 663.3             | 726.1                |
| Noncontrolling interest in consolidated subsidiaries                                                                                                                                                            | 7.1               | 6.8                  |
| Total shareholders' equity                                                                                                                                                                                      | 670.4             | 732.9                |
| Total liabilities and shareholders' equity                                                                                                                                                                      | <u>\$ 1,720.5</u> | <u>\$ 1,730.0</u>    |

*The accompanying notes are an integral part of these statements.*

**BRUKER CORPORATION**  
**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME**  
(in millions, except per share data)

|                                                                                     | Three Months Ended June 30, |          | Six Months Ended June 30, |          |
|-------------------------------------------------------------------------------------|-----------------------------|----------|---------------------------|----------|
|                                                                                     | 2016                        | 2015     | 2016                      | 2015     |
| Product revenue                                                                     | \$ 305.6                    | \$ 336.2 | \$ 617.9                  | \$ 634.2 |
| Service revenue                                                                     | 63.5                        | 58.2     | 124.2                     | 112.3    |
| Other revenue                                                                       | 2.6                         | 1.6      | 5.0                       | 3.0      |
| Total revenue                                                                       | 371.7                       | 396.0    | 747.1                     | 749.5    |
| Cost of product revenue                                                             | 162.3                       | 191.5    | 332.5                     | 352.7    |
| Cost of service revenue                                                             | 38.0                        | 35.0     | 75.4                      | 66.9     |
| Cost of other revenue                                                               | 1.3                         | 0.1      | 2.3                       | 0.3      |
| Total cost of revenue                                                               | 201.6                       | 226.6    | 410.2                     | 419.9    |
| Gross profit                                                                        | 170.1                       | 169.4    | 336.9                     | 329.6    |
| Operating expenses:                                                                 |                             |          |                           |          |
| Selling, general and administrative                                                 | 100.9                       | 98.5     | 193.6                     | 193.1    |
| Research and development                                                            | 36.8                        | 37.5     | 72.9                      | 74.7     |
| Other charges, net                                                                  | 12.0                        | 1.8      | 16.0                      | 15.0     |
| Total operating expenses                                                            | 149.7                       | 137.8    | 282.5                     | 282.8    |
| Operating income                                                                    | 20.4                        | 31.6     | 54.4                      | 46.8     |
| Interest and other income (expense), net                                            | (2.6)                       | (6.2)    | (8.2)                     | (9.7)    |
| Income before income taxes and noncontrolling interest in consolidated subsidiaries | 17.8                        | 25.4     | 46.2                      | 37.1     |
| Income tax provision                                                                | 3.0                         | 2.3      | 7.8                       | 7.1      |
| Consolidated net income                                                             | 14.8                        | 23.1     | 38.4                      | 30.0     |
| Net income attributable to noncontrolling interest in consolidated subsidiaries     | 0.3                         | 1.2      | 0.3                       | 1.6      |
| Net income attributable to Bruker Corporation                                       | \$ 14.5                     | \$ 21.9  | \$ 38.1                   | \$ 28.4  |
| Net income per common share attributable to Bruker Corporation shareholders:        |                             |          |                           |          |
| Basic and diluted                                                                   | \$ 0.09                     | \$ 0.13  | \$ 0.23                   | \$ 0.17  |
| Weighted average common shares outstanding:                                         |                             |          |                           |          |
| Basic                                                                               | 161.4                       | 168.3    | 162.3                     | 168.3    |
| Diluted                                                                             | 162.4                       | 169.7    | 163.3                     | 169.7    |
| Comprehensive income                                                                | \$ (2.2)                    | \$ 59.4  | \$ 54.0                   | \$ 1.7   |
| Less: Comprehensive income attributable to noncontrolling interests                 | 0.1                         | 0.8      | 0.3                       | 1.2      |
| Comprehensive income attributable to Bruker Corporation                             | \$ (2.3)                    | \$ 58.6  | \$ 53.7                   | \$ 0.5   |
| Dividend declared                                                                   | \$ 0.04                     | \$ —     | \$ 0.08                   | \$ —     |

*The accompanying notes are an integral part of these statements.*

**BRUKER CORPORATION**  
**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(in millions)

|                                                                                           | <b>Six Months Ended June 30,</b> |                 |
|-------------------------------------------------------------------------------------------|----------------------------------|-----------------|
|                                                                                           | <b>2016</b>                      | <b>2015</b>     |
| Cash flows from operating activities:                                                     |                                  |                 |
| Consolidated net income                                                                   | \$ 38.4                          | \$ 30.0         |
| Adjustments to reconcile consolidated net income to cash flows from operating activities: |                                  |                 |
| Depreciation and amortization                                                             | 26.7                             | 26.7            |
| Write-down of demonstration inventories to net realizable value                           | 8.5                              | 9.9             |
| Stock-based compensation expense                                                          | 4.3                              | 3.6             |
| Deferred income taxes                                                                     | (4.0)                            | (0.6)           |
| Loss on disposal of product line                                                          | —                                | 0.2             |
| Other non-cash expenses, net                                                              | 9.0                              | 0.9             |
| Changes in operating assets and liabilities, net of acquisitions and divestitures:        |                                  |                 |
| Accounts receivable                                                                       | 30.3                             | 42.6            |
| Inventories                                                                               | (60.0)                           | (38.9)          |
| Accounts payable and accrued expenses                                                     | (12.3)                           | (7.3)           |
| Income taxes payable, net                                                                 | (31.4)                           | (16.7)          |
| Deferred revenue                                                                          | 5.4                              | (1.1)           |
| Customer advances                                                                         | (6.4)                            | (7.4)           |
| Other changes in operating assets and liabilities, net                                    | (4.4)                            | (16.4)          |
| Net cash provided by operating activities                                                 | <u>4.1</u>                       | <u>25.5</u>     |
| Cash flows from investing activities:                                                     |                                  |                 |
| Purchases of short-term investments                                                       | (33.1)                           | (49.1)          |
| Maturities of short-term investments                                                      | 50.1                             | 40.3            |
| Cash paid for acquisitions, net of cash acquired                                          | (1.2)                            | —               |
| Purchases of property, plant and equipment                                                | (17.2)                           | (13.4)          |
| Proceeds from sales of property, plant and equipment                                      | 0.9                              | 0.7             |
| Net cash used in investing activities                                                     | <u>(0.5)</u>                     | <u>(21.5)</u>   |
| Cash flows from financing activities:                                                     |                                  |                 |
| Proceeds from revolving lines of credit                                                   | 77.0                             | 10.0            |
| Proceeds (repayment) of other debt, net                                                   | 0.2                              | (0.2)           |
| Proceeds from issuance of common stock, net                                               | 9.6                              | 6.2             |
| Payment of contingent consideration                                                       | —                                | (3.0)           |
| Repurchase of common stock                                                                | (117.6)                          | (17.2)          |
| Changes in restricted cash                                                                | 0.7                              | 1.4             |
| Payment of dividends                                                                      | (13.0)                           | —               |
| Cash payments to noncontrolling interest                                                  | —                                | (0.5)           |
| Excess tax benefits related to stock option awards                                        | 0.3                              | 2.2             |
| Net cash used in financing activities                                                     | <u>(42.8)</u>                    | <u>(1.1)</u>    |
| Effect of exchange rate changes on cash and cash equivalents                              | <u>4.6</u>                       | <u>(1.6)</u>    |
| Net change in cash and cash equivalents                                                   | (34.6)                           | 1.3             |
| Cash and cash equivalents at beginning of period                                          | 267.1                            | 319.5           |
| Cash and cash equivalents at end of period                                                | <u>\$ 232.5</u>                  | <u>\$ 320.8</u> |

*The accompanying notes are an integral part of these statements.*

**BRUKER CORPORATION**  
**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**1. Description of Business**

Bruker Corporation, together with its consolidated subsidiaries (“Bruker” or the “Company”), is a designer and manufacturer of high-performance scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. Many of the Company’s products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. The Company’s products address the rapidly evolving needs of a diverse array of customers in life science research, pharmaceuticals, biotechnology, applied markets, cell biology, clinical research, microbiology, in-vitro diagnostics, nanotechnology and materials science research.

The Company has two reportable segments, *Bruker Scientific Instruments (BSI)*, which represents approximately 93% of the Company’s revenues during the three and six months ended June 30, 2016, and *Bruker Energy & Supercon Technologies (BEST)*, which represents the remainder of the Company’s revenues. Within BSI, the Company is organized into three operating segments: the Bruker BioSpin Group, the Bruker CALID Group and the Bruker Nano Group. For financial reporting purposes, the Bruker BioSpin, Bruker CALID and Bruker Nano operating segments are aggregated into the BSI reportable segment because each has similar economic characteristics, production processes, service offerings, types and classes of customers, methods of distribution and regulatory environments.

*Bruker BioSpin* - The Bruker BioSpin Group manufactures and distributes enabling life science tools based on magnetic resonance technology. The majority of Bruker BioSpin’s revenues are generated by academic and government research customers. Other customers include pharmaceutical and biotechnology companies and nonprofit laboratories, as well as chemical, food and beverage, clinical and polymer companies.

*Bruker CALID* (*C*hemicals, *A*ppplied Markets, *L*ife Science, *I*n-Vitro Diagnostics, *D*etection) - The Bruker CALID Group designs, manufactures and distributes life science mass spectrometry and ion mobility spectrometry systems, infrared spectroscopy and radiological/nuclear detectors for Chemical, Biological, Radiological, Nuclear and Explosive (CBRNE) detection in emergency response, homeland security and defense applications, and analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. Customers of the Bruker CALID Group include pharmaceutical, biotechnology and diagnostics companies, contract research organizations, academic institutions, medical schools, nonprofit or for-profit forensics, agriculture, food and beverage safety, environmental and clinical microbiology laboratories, hospitals and government departments and agencies.

*Bruker Nano* - The Bruker Nano Group designs, manufactures and distributes advanced X-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, handheld, portable and mobile X-ray fluorescence spectrometry instruments and spark optical emission spectroscopy systems. Customers of the Bruker Nano Group include biotechnology and pharmaceutical companies, academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies and other businesses involved in materials analysis.

The Company’s BEST reportable segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and “big science” research. The segment focuses on metallic low temperature superconductors for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications, as well as ceramic high temperature superconductors primarily for energy grid and magnet applications.

The unaudited condensed consolidated financial statements represent the consolidated accounts of the Company. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements as of June 30, 2016 and December 31, 2015, and for the three and six months ended June 30, 2016 and 2015, have been prepared in accordance with accounting principles generally accepted in the United States of

America (GAAP) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial information presented herein does not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation have been included. The results for interim periods are not necessarily indicative of the results expected for any other interim period or the full year. Upon adoption of Accounting Standards Update 2015-03, the deferred financing costs related to the Company's senior note obligations were reclassified as of December 31, 2015 to conform to the current year presentation and had no effect on previously reported net income or cash flows. See Note 7 for additional information regarding the Company's senior note obligations.

At June 30, 2016, the Company's significant accounting policies and estimates, which are detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, have not changed.

## 2. Stock-Based Compensation

In May 2010, the Bruker Corporation 2010 Incentive Compensation Plan (the "2010 Plan") was approved by the Company's stockholders. The 2010 Plan provided for the issuance of up to 8,000,000 shares of the Company's common stock. The 2010 Plan allowed a committee of the Board of Directors (the "Compensation Committee") to grant incentive stock options, non-qualified stock options and restricted stock awards. The Compensation Committee had the authority to determine which employees would receive the awards, the amount of the awards and other terms and conditions of any awards. Awards granted under the 2010 Plan typically were made subject to a vesting period of three to five years.

In May 2016, the Bruker Corporation 2016 Incentive Compensation Plan (the "2016 Plan") was approved by the Company's stockholders. With the approval of the 2016 Plan, no further grants will be made under the 2010 Plan. The 2016 Plan provides for the issuance of up to 9,500,000 shares of the Company's common stock and permits the grant of awards of non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock, unrestricted stock, restricted stock units, performance shares and performance units, as well as cash-based awards. The 2016 Plan is administered by the Compensation Committee. The Compensation Committee has the authority to determine which employees will receive awards, the amount of any awards, and other terms and conditions of such awards. Awards granted under the 2016 Plan typically vest over a period of three to four years.

The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of income and comprehensive income (in millions):

|                                | Three Months Ended June 30, |        | Six Months Ended June 30, |        |
|--------------------------------|-----------------------------|--------|---------------------------|--------|
|                                | 2016                        | 2015   | 2016                      | 2015   |
| Stock options                  | \$ 1.7                      | \$ 1.5 | \$ 3.5                    | \$ 3.3 |
| Restricted stock awards        | 0.4                         | (0.1)  | 0.8                       | 0.3    |
| Restricted stock units         | —                           | —      | —                         | —      |
| Total stock-based compensation | \$ 2.1                      | \$ 1.4 | \$ 4.3                    | \$ 3.6 |

  

|                                     | Three Months Ended June 30, |        | Six Months Ended June 30, |        |
|-------------------------------------|-----------------------------|--------|---------------------------|--------|
|                                     | 2016                        | 2015   | 2016                      | 2015   |
| Costs of product revenue            | \$ 0.3                      | \$ 0.2 | \$ 0.6                    | \$ 0.5 |
| Selling, general and administrative | 1.5                         | 1.0    | 3.1                       | 2.6    |
| Research and development            | 0.3                         | 0.2    | 0.6                       | 0.5    |
| Total stock-based compensation      | \$ 2.1                      | \$ 1.4 | \$ 4.3                    | \$ 3.6 |

Stock-based compensation expense is recognized on a straight-line basis over the underlying requisite service period of the stock-based award.

Stock options to purchase the Company's common stock are periodically awarded to executive officers and other employees of the Company subject to a vesting period of three to five years. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. Assumptions for the six months ended June 30, 2016 and 2015 regarding volatility, expected life, dividend yield and risk-free interest rates are required for the Black-Scholes model and are presented in the table below:

|                          | 2016              | 2015            |
|--------------------------|-------------------|-----------------|
| Risk-free interest rates | 1.27% - 2.05%     | 1.58% - 1.71%   |
| Expected life            | 5.75 - 7.02 years | 6.0 - 6.3 years |
| Volatility               | 33.75% - 41.60%   | 37.15% - 52.23% |
| Expected dividend yield  | 0.0% - 0.66%      | 0.0%            |

Stock option activity for the six months ended June 30, 2016 was as follows:

|                                                       | Shares Subject to Options | Weighted Average Option Price | Weighted Average Remaining Contractual Term (Yrs) | Aggregate Intrinsic Value (in millions) (b) |
|-------------------------------------------------------|---------------------------|-------------------------------|---------------------------------------------------|---------------------------------------------|
| Outstanding at December 31, 2015                      | 4,637,279                 | \$ 16.72                      |                                                   |                                             |
| Granted                                               | 244,200                   | 24.73                         |                                                   |                                             |
| Exercised                                             | (723,679)                 | 13.32                         |                                                   |                                             |
| Forfeited                                             | (151,854)                 | 18.80                         |                                                   |                                             |
| Outstanding at June 30, 2016                          | 4,005,946                 | \$ 17.74                      | 6.6                                               | \$ 20.5                                     |
| Exercisable at June 30, 2016                          | 1,788,225                 | \$ 14.85                      | 4.7                                               | \$ 14.1                                     |
| Exercisable and expected to vest at June 30, 2016 (a) | 3,867,117                 | \$ 17.66                      | 6.6                                               | \$ 20.1                                     |

- (a) In addition to the options that are vested at June 30, 2016, the Company expects a portion of the unvested options to vest in the future. Options expected to vest in the future are determined by applying an estimated forfeiture rate to the options that are unvested as of June 30, 2016.
- (b) The aggregate intrinsic value is based on the positive difference between the fair value of the Company's common stock price of \$22.74 on June 30, 2016, or the date of exercises, as appropriate, and the exercise price of the underlying stock options.

The weighted average fair value of options granted was \$9.77 and \$8.61 per share for the six months ended June 30, 2016 and 2015, respectively.

The total intrinsic value of options exercised was \$9.7 million and \$4.7 million for the six months ended June 30, 2016 and 2015, respectively.

Restricted stock award activity for the six months ended June 30, 2016 was as follows:

|                                  | Shares Subject to Restriction | Weighted Average Grant Date Fair Value |
|----------------------------------|-------------------------------|----------------------------------------|
| Outstanding at December 31, 2015 | 243,150                       | \$ 18.58                               |
| Granted                          | 13,105                        | 24.80                                  |
| Vested                           | (9,683)                       | 17.73                                  |
| Forfeited                        | (1,375)                       | 16.57                                  |
| Outstanding at June 30, 2016     | 245,197                       | \$ 18.96                               |

The total fair value of restricted stock vested was \$0.2 million for the each of the six months ended June 30, 2016 and 2015, respectively.

Restricted stock unit activity for the six months ended June 30, 2016 was as follows:

|                                  | Shares Subject<br>to Restriction | Weighted<br>Average Grant<br>Date Fair<br>Value |
|----------------------------------|----------------------------------|-------------------------------------------------|
| Outstanding at December 31, 2015 | —                                | \$ —                                            |
| Granted                          | 7,762                            | 26.29                                           |
| Outstanding at June 30, 2016     | <u>7,762</u>                     | <u>\$ 26.29</u>                                 |

No restricted stock units vested in the six months ended June 30, 2016.

At June 30, 2016, the Company expects to recognize pre-tax stock-based compensation expense of \$13.3 million associated with outstanding stock option awards granted under the Company's stock plans over the weighted average remaining service period of 2.42 years. The Company expects to recognize additional pre-tax stock-based compensation expense of \$3.2 million associated with outstanding restricted stock awards granted under the Company's stock plans over the weighted average remaining service period of 2.56 years. The Company also expects to recognize additional pre-tax stock-based compensation expense of \$0.2 million associated with outstanding restricted stock units granted under the 2016 Plan over the weighted average remaining service period of 3.92 years.

### 3. Earnings Per Share

Net income per common share attributable to Bruker Corporation shareholders is calculated by dividing net income attributable to Bruker Corporation by the weighted average shares outstanding during the period. The diluted net income per share computation includes the effect of shares which would be issuable upon the exercise of outstanding stock options and the vesting of restricted stock, reduced by the number of shares which are assumed to be purchased by the Company under the treasury stock method.

The following table sets forth the computation of basic and diluted weighted average shares outstanding and net income per common share attributable to Bruker Corporation shareholders (in millions, except per share amounts):

|                                                                              | Three Months Ended June 30, |                | Six Months Ended June 30, |                |
|------------------------------------------------------------------------------|-----------------------------|----------------|---------------------------|----------------|
|                                                                              | 2016                        | 2015           | 2016                      | 2015           |
| Net income attributable to Bruker Corporation, as reported                   | <u>\$ 14.5</u>              | <u>\$ 21.9</u> | <u>\$ 38.1</u>            | <u>\$ 28.4</u> |
| Weighted average shares outstanding:                                         |                             |                |                           |                |
| Weighted average shares outstanding-basic                                    | 161.4                       | 168.3          | 162.3                     | 168.3          |
| Effect of dilutive securities:                                               |                             |                |                           |                |
| Stock options and restricted stock                                           | <u>1.0</u>                  | <u>1.4</u>     | <u>1.0</u>                | <u>1.4</u>     |
|                                                                              | <u>162.4</u>                | <u>169.7</u>   | <u>163.3</u>              | <u>169.7</u>   |
| Net income per common share attributable to Bruker Corporation shareholders: |                             |                |                           |                |
| Basic and diluted                                                            | <u>\$ 0.09</u>              | <u>\$ 0.13</u> | <u>\$ 0.23</u>            | <u>\$ 0.17</u> |

Stock options to purchase approximately 1.0 million shares and 0.9 million shares were excluded from the computation of diluted earnings per share in the three months ended June 30, 2016 and 2015, respectively, as their effect would have been anti-dilutive. Approximately 1.8 million shares and 1.4 million shares were excluded from the computation of diluted earnings per share in the six months ended June 30, 2016 and 2015, respectively.

### 4. Fair Value of Financial Instruments

The Company applies the following hierarchy to determine the fair value of financial instruments, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The levels in the hierarchy are defined as follows:

- *Level 1:* Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
- *Level 2:* Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
- *Level 3:* Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The valuation techniques that may be used by the Company to determine the fair value of Level 2 and Level 3 financial instruments are the market approach, the income approach and the cost approach. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value based on current market expectations about those future amounts, including present value techniques, option-pricing models and the excess earnings method. The cost approach is based on the amount that would be required to replace the service capacity of an asset (replacement cost).

The following tables set forth the Company's financial instruments that are measured at fair value on a recurring basis and presents them within the fair value hierarchy using the lowest level of input that is significant to the fair value measurement at June 30, 2016 and December 31, 2015 (in millions):

|                                                         |                | Quoted Prices<br>in Active<br>Markets<br>Available<br>(Level 1) | Significant<br>Other<br>Observable<br>Inputs<br>(Level 2) | Significant<br>Unobservable<br>Inputs<br>(Level 3) |
|---------------------------------------------------------|----------------|-----------------------------------------------------------------|-----------------------------------------------------------|----------------------------------------------------|
| <b>June 30, 2016</b>                                    | <b>Total</b>   |                                                                 |                                                           |                                                    |
| <b>Assets:</b>                                          |                |                                                                 |                                                           |                                                    |
| Foreign exchange contracts                              | \$ 0.2         | \$ —                                                            | \$ 0.2                                                    | \$ —                                               |
| Embedded derivatives in purchase and delivery contracts | 0.1            | —                                                               | 0.1                                                       | —                                                  |
| Total assets recorded at fair value                     | <u>\$ 0.3</u>  | <u>\$ —</u>                                                     | <u>\$ 0.3</u>                                             | <u>\$ —</u>                                        |
| <b>Liabilities:</b>                                     |                |                                                                 |                                                           |                                                    |
| Contingent consideration                                | \$ 12.8        | \$ —                                                            | \$ —                                                      | \$ 12.8                                            |
| Foreign exchange contracts                              | 0.9            | —                                                               | 0.9                                                       | —                                                  |
| Embedded derivatives in purchase and delivery contracts | 0.4            | —                                                               | 0.4                                                       | —                                                  |
| Fixed price commodity contracts                         | 0.2            | —                                                               | 0.2                                                       | —                                                  |
| Total liabilities recorded at fair value                | <u>\$ 14.3</u> | <u>\$ —</u>                                                     | <u>\$ 1.5</u>                                             | <u>\$ 12.8</u>                                     |
|                                                         |                |                                                                 |                                                           |                                                    |
|                                                         |                | Quoted Prices<br>in Active<br>Markets<br>Available<br>(Level 1) | Significant<br>Other<br>Observable<br>Inputs<br>(Level 2) | Significant<br>Unobservable<br>Inputs<br>(Level 3) |
| <b>December 31, 2015</b>                                | <b>Total</b>   |                                                                 |                                                           |                                                    |
| <b>Assets:</b>                                          |                |                                                                 |                                                           |                                                    |
| Embedded derivatives in purchase and delivery contracts | \$ 0.5         | \$ —                                                            | \$ 0.5                                                    | \$ —                                               |
| Total assets recorded at fair value                     | <u>\$ 0.5</u>  | <u>\$ —</u>                                                     | <u>\$ 0.5</u>                                             | <u>\$ —</u>                                        |
| <b>Liabilities:</b>                                     |                |                                                                 |                                                           |                                                    |
| Contingent consideration                                | \$ 4.6         | \$ —                                                            | \$ —                                                      | \$ 4.6                                             |
| Foreign exchange contracts                              | 1.3            | —                                                               | 1.3                                                       | —                                                  |
| Embedded derivatives in purchase and delivery contracts | 0.5            | —                                                               | 0.5                                                       | —                                                  |
| Fixed price commodity contracts                         | 0.4            | —                                                               | 0.4                                                       | —                                                  |
| Total liabilities recorded at fair value                | <u>\$ 6.8</u>  | <u>\$ —</u>                                                     | <u>\$ 2.2</u>                                             | <u>\$ 4.6</u>                                      |

The Company's financial instruments consist primarily of short-term investments, restricted cash, derivative instruments consisting of foreign exchange contracts, commodity contracts, derivatives embedded in certain purchase and sale contracts, accounts receivable, short-term borrowings, accounts payable, contingent consideration and long-term debt. The carrying amounts of the Company's short-term investments, restricted cash, accounts receivable, short-term borrowings and accounts payable approximate fair value due to their short-term nature. Derivative assets and liabilities are measured at fair value on a recurring basis. The Company's long-term debt consists principally of a private placement arrangement entered into in 2012 with various fixed interest rates based on the maturity date. The fair value of the long-term fixed interest rate debt, which has been classified as Level 2, was \$264.1 million and \$252.1 million at June 30, 2016 and December 31, 2015, respectively, based on market and observable sources with similar maturity dates.

Fair value treatment may be elected either upon initial recognition of an eligible asset or liability or, for an existing asset or liability, if an event triggers a new basis of accounting. The Company did not elect to remeasure any of its existing financial assets or liabilities and did not elect the fair value option for any financial assets or liabilities which originated during the three or six months ended June 30, 2016 or 2015.

As part of certain historical acquisitions, the Company recorded contingent consideration liabilities that have been classified as Level 3 in the fair value hierarchy. The contingent consideration represents the estimated fair value of future payments to the former shareholders of applicable acquired companies based on achieving annual revenue and gross margin targets in certain years as specified in the purchase and sale agreements. The Company initially values contingent consideration using a Monte Carlo simulation which models future revenue and costs of goods sold projections and discounts the average results to present value. For the three months ended June 30, 2016, additional contingent consideration of \$7.7 million was recognized in earnings related to a recent acquisition within the Bruker Nano Group based upon an increase in forecasted revenue levels for the acquired business for the remainder of 2016 and was recorded within other charges, net in the unaudited condensed consolidated statements of income and comprehensive income.

The following table sets forth the changes in contingent consideration liabilities for the six months ended June 30, 2016 (in millions):

|                              |    |             |
|------------------------------|----|-------------|
| Balance at December 31, 2015 | \$ | 4.6         |
| Current period additions     |    | 0.5         |
| Current period adjustments   |    | 7.7         |
| Balance at June 30, 2016     | \$ | <u>12.8</u> |

For the three and six months ended June 30, 2015, the changes to the fair value of the contingent consideration recognized in earnings was (\$3.1) million and (\$3.0) million, respectively, and was recorded within other charges, net in the unaudited condensed consolidated statements of income and comprehensive income.

The Company enters into time deposits with varying maturity dates ranging from one to twelve months, as well as call deposits for which the Company has the ability to redeem the invested amounts over a period of 31 to 95 days. The Company has classified these investments within cash and cash equivalents or short-term investments within the unaudited condensed consolidated balance sheet based on the call and maturity dates. As of June 30, 2016 there are no cash equivalents outstanding and \$187.9 million of short-term investments.

Short-term investments are classified as available-for-sale and are reported at fair value, with unrealized gains (losses) excluded from earnings and reported, net of tax, in accumulated other comprehensive income (loss) within the accompanying unaudited condensed consolidated balance sheet. There were no unrealized gains (losses) recorded during the three or six months ended June 30, 2016 and 2015. On a quarterly basis, the Company reviews its short-term investments to determine if there have been any events that could create an impairment. None were noted for the three or six months ended June 30, 2016 and 2015.

## 5. Inventories

Inventories consisted of the following (in millions):

|                     | June 30,<br>2016 | December 31,<br>2015 |
|---------------------|------------------|----------------------|
| Raw materials       | \$ 151.9         | \$ 158.8             |
| Work-in-process     | 187.3            | 131.1                |
| Finished goods      | 95.0             | 93.3                 |
| Demonstration units | 36.8             | 38.8                 |
| <b>Inventories</b>  | <b>\$ 471.0</b>  | <b>\$ 422.0</b>      |

Finished goods include in-transit systems that have been shipped to the Company's customers, but not yet installed and accepted by the customer. As of June 30, 2016 and December 31, 2015, inventory-in-transit was \$36.8 million and \$44.7 million, respectively.

The Company reduces the carrying value of its demonstration inventories for differences between its cost and estimated net realizable value through a charge to cost of product revenue that is based on a number of factors, including the age of the unit, the physical condition of the unit and an assessment of technological obsolescence. Amounts recorded in Cost of Revenue related to the write-down of demonstration units to net realizable value were \$3.7 million and \$4.9 million for the three months ended June 30, 2016 and 2015, respectively, and \$8.5 million and \$9.9 million for the six months ended June 30, 2016 and 2015, respectively.

## 6. Goodwill and Other Intangible Assets

The following table sets forth the changes in the carrying amount of goodwill for the six months ended June 30, 2016 (in millions):

|                                 |                 |
|---------------------------------|-----------------|
| Balance at December 31, 2015    | \$ 130.6        |
| Foreign currency effect         | 0.4             |
| <b>Balance at June 30, 2016</b> | <b>\$ 131.0</b> |

The following is a summary of intangible assets (in millions):

|                                           | June 30, 2016               |                             |                        | December 31, 2015           |                             |                        |
|-------------------------------------------|-----------------------------|-----------------------------|------------------------|-----------------------------|-----------------------------|------------------------|
|                                           | Gross<br>Carrying<br>Amount | Accumulated<br>Amortization | Net Carrying<br>Amount | Gross<br>Carrying<br>Amount | Accumulated<br>Amortization | Net Carrying<br>Amount |
| Existing technology and related patents   | \$ 156.0                    | \$ (104.4)                  | \$ 51.6                | \$ 154.5                    | \$ (95.5)                   | \$ 59.0                |
| Customer relationships                    | 18.3                        | (6.9)                       | 11.4                   | 18.4                        | (5.9)                       | 12.5                   |
| Non compete contracts                     | 1.8                         | (0.9)                       | 0.9                    | 1.8                         | (0.6)                       | 1.2                    |
| Trade names                               | 1.6                         | (0.3)                       | 1.3                    | 1.6                         | (0.2)                       | 1.4                    |
| Intangible assets subject to amortization | 177.7                       | (112.5)                     | 65.2                   | 176.3                       | (102.2)                     | 74.1                   |
| In-process research and development       | 0.6                         | —                           | 0.6                    | 0.6                         | —                           | 0.6                    |
| <b>Intangible assets</b>                  | <b>\$ 178.3</b>             | <b>\$ (112.5)</b>           | <b>\$ 65.8</b>         | <b>\$ 176.9</b>             | <b>\$ (102.2)</b>           | <b>\$ 74.7</b>         |

For the three months ended June 30, 2016 and 2015, the Company recorded amortization expense of \$5.4 million and \$5.2 million, respectively, related to intangible assets subject to amortization. For the six months ended June 30, 2016 and 2015, the Company recorded amortization expense of \$10.8 million and \$10.4 million, respectively, related to intangible assets subject to amortization.

## 7. Debt

The Company's debt obligations as of June 30, 2016 and December 31, 2015 consisted of the following (in millions):

|                                                                   | June 30,<br>2016 | December 31,<br>2015 |
|-------------------------------------------------------------------|------------------|----------------------|
| US Dollar revolving loan under the 2015 Credit Agreement          | \$ 102.0         | \$ 25.0              |
| US Dollar notes under the Note Purchase Agreement                 | 240.0            | 240.0                |
| Unamortized debt issuance costs under the Note Purchase Agreement | (0.9)            | (0.9)                |
| Capital lease obligations and other loans                         | 1.9              | 1.7                  |
| <b>Total debt</b>                                                 | <b>343.0</b>     | <b>265.8</b>         |
| Current portion of long-term debt                                 | (20.3)           | (0.6)                |
| <b>Total long-term debt, less current portion</b>                 | <b>\$ 322.7</b>  | <b>\$ 265.2</b>      |

On October 27, 2015, the Company entered into a revolving credit agreement, referred to as the 2015 Credit Agreement, and terminated the prior credit agreement. The 2015 Credit Agreement provides a maximum commitment on the Company's revolving credit line of \$500.0 million and a maturity date of October 2020. Borrowings under the revolving credit line of the 2015 Credit Agreement accrue interest, at the Company's option, at either (a) the greatest of (i) the prime rate, (ii) the federal funds rate plus 0.50% and (iii) adjusted LIBOR plus 1.00%, plus margins ranging from 0.00% to 0.30% or (b) LIBOR, plus margins ranging from 0.90% to 1.30%. There is also a facility fee ranging from 0.10% to 0.20%.

Borrowings under the 2015 Credit Agreement are secured by guarantees from certain material subsidiaries, as defined in the 2015 Credit Agreement. The 2015 Credit Agreement also requires the Company to maintain certain financial ratios related to maximum leverage and minimum interest coverage. Specifically, the Company's leverage ratio cannot exceed 3.5 and the Company's interest coverage ratio cannot be less than 2.5. In addition to the financial ratios, the 2015 Credit Agreement contains negative covenants, including among others, restrictions on liens, indebtedness of the Company and its subsidiaries, asset sales, dividends and transactions with affiliates. Failure to comply with any of these restrictions or covenants may result in an event of default on the 2015 Credit Agreement, which could permit acceleration of the debt and require the Company to prepay the debt before its scheduled due date.

As of June 30, 2016, the Company was in compliance with the covenants of the 2015 Credit Agreement. The Company's leverage ratio (as defined in the 2015 Credit Agreement) was 1.3 and interest coverage ratio (as defined in the 2015 Credit Agreement) was 15.2.

The following is a summary of the maximum commitments and the net amounts available to the Company under the 2015 Credit Agreement and other lines of credit with various financial institutions located primarily in Germany and Switzerland that are unsecured and typically due upon demand with interest payable monthly, at June 30, 2016 (in millions):

|                                        | Weighted<br>Average<br>Interest Rate | Total Amount<br>Committed by<br>Lenders | Outstanding<br>Borrowings | Outstanding<br>Lines of Credit | Total Amount<br>Available |
|----------------------------------------|--------------------------------------|-----------------------------------------|---------------------------|--------------------------------|---------------------------|
| 2015 Credit Agreement                  | 1.6%                                 | \$ 500.0                                | \$ 102.0                  | \$ 1.1                         | \$ 396.9                  |
| Other lines of credit                  | —                                    | 238.0                                   | —                         | 129.2                          | 108.8                     |
| <b>Total revolving lines of credit</b> |                                      | <b>\$ 738.0</b>                         | <b>\$ 102.0</b>           | <b>\$ 130.3</b>                | <b>\$ 505.7</b>           |

In January 2012, the Company entered into a note purchase agreement, referred to as the Note Purchase Agreement, with a group of accredited institutional investors. Pursuant to the Note Purchase Agreement, the Company issued and sold \$240.0 million of senior notes, referred to as the Senior Notes, which consist of the following:

- \$20.0 million 3.16% Series 2012A Senior Notes, Tranche A, due January 18, 2017;
- \$15.0 million 3.74% Series 2012A Senior Notes, Tranche B, due January 18, 2019;
- \$105.0 million 4.31% Series 2012A Senior Notes, Tranche C, due January 18, 2022; and
- \$100.0 million 4.46% Series 2012A Senior Notes, Tranche D, due January 18, 2024.

Under the terms of the Note Purchase Agreement, the Company may issue and sell additional senior notes up to an aggregate principal amount of \$600 million, subject to certain conditions. Interest on the Senior Notes is payable semi-annually

on January 18 and July 18 of each year. The Senior Notes are unsecured obligations of the Company and are fully and unconditionally guaranteed by certain of the Company's direct and indirect subsidiaries. The Senior Notes rank pari passu in right of repayment with the Company's other senior unsecured indebtedness. The Company may prepay some or all of the Senior Notes at any time in an amount not less than 10% of the original aggregate principal amount of the Senior Notes to be prepaid, at a price equal to the sum of (a) 100% of the principal amount thereof, plus accrued and unpaid interest, and (b) the applicable make-whole amount, upon not less than 30 and no more than 60 days written notice to the holders of the Senior Notes. In the event of a change in control of the Company, as defined in the Note Purchase Agreement, the Company may be required to prepay the Senior Notes at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest.

The Note Purchase Agreement contains affirmative covenants, including, without limitation, maintenance of corporate existence, compliance with laws, maintenance of insurance and properties, payment of taxes, addition of subsidiary guarantors and furnishing notices and other information. The Note Purchase Agreement also contains certain restrictive covenants that restrict the Company's ability to, among other things, incur liens, transfer or sell assets, engage in certain mergers and consolidations and enter into transactions with affiliates. The Note Purchase Agreement also includes customary representations and warranties and events of default. In the case of an event of default arising from specified events of bankruptcy or insolvency, all outstanding Senior Notes will become due and payable immediately without further action or notice. In the case of payment events of defaults, any holder of Senior Notes affected thereby may declare all Senior Notes held by it due and payable immediately. In the case of any other event of default, a majority of the holders of the Senior Notes may declare all the Senior Notes to be due and payable immediately. Pursuant to the Note Purchase Agreement, so long as any Senior Notes are outstanding the Company will not permit (i) its leverage ratio, as determined pursuant to the Note Purchase Agreement, as of the end of any fiscal quarter to exceed 3.50 to 1.00, (ii) its interest coverage ratio as determined pursuant to the Note Purchase Agreement as of the end of any fiscal quarter for any period of four consecutive fiscal quarters to be less than 2.50 to 1 or (iii) priority debt at any time to exceed 25% of consolidated net worth, as determined pursuant to the Note Purchase Agreement.

As of June 30, 2016, the Company was in compliance with the covenants of the Note Purchase Agreement. The Company's leverage ratio (as defined in the Note Purchase Agreement) was 1.3 and interest coverage ratio (as defined in the Note Purchase Agreement) was 15.2.

In April 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2015-03, *Simplifying the Presentation of Debt Issuance Costs*, which amends the existing guidance to require that debt issuance costs be presented in the unaudited condensed consolidated balance sheet as a reduction from the carrying amount of the related debt liability instead of as an other asset. The Company adopted ASU 2015-03 on a retrospective basis for the six months ended June 30, 2016. As of June 30, 2016 and December 31, 2015, there were \$0.9 million in debt issuance costs recorded as a reduction in the carrying value of the related debt liability under the Note Purchase Agreement. The \$0.9 million in debt issuance costs as of June 30, 2016 will be amortized over the remaining term of the Note Purchase Agreement. The retrospective adoption resulted in \$0.9 million of debt issuance costs being reclassified from other current assets and other non-current assets to a reduction of the carrying value of long-term debt as of December 31, 2015. The Company also adopted ASU No. 2015-15, *Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements*, and elected not to reclassify the debt issuance costs related to line-of-credit arrangements for the 2015 Credit Agreement.

## **8. Derivative Instruments and Hedging Activities**

### ***Interest Rate Risks***

The Company's exposure to interest rate risk relates primarily to outstanding variable rate debt and adverse movements in the related short-term market rates. The most significant component of the Company's interest rate risk relates to amounts outstanding under the 2015 Credit Agreement, which totaled \$102.0 million at June 30, 2016. The Company currently has a higher level of fixed rate debt than variable rate debt, which limits the exposure to adverse movements in interest rates.

### ***Foreign Exchange Rate Risk Management***

The Company generates a substantial portion of its revenues and expenses in international markets, principally Germany and other countries in the European Union, Switzerland and Japan, which subjects its operations to the impact of exchange rate fluctuations. The impact of currency exchange rate movement can be positive or negative in any period. The Company periodically enters into foreign exchange contracts in order to minimize the volatility that fluctuations in foreign currency have

on its monetary transactions. Under these arrangements, the Company typically agrees to purchase a fixed amount of a foreign currency in exchange for a fixed amount of U.S. Dollars or other currencies on specified dates with maturities of less than twelve months. These transactions do not qualify for hedge accounting and, accordingly, the instrument is recorded at fair value with the corresponding gains and losses recorded in the unaudited condensed consolidated statements of income and comprehensive income. The Company had the following notional amounts outstanding under foreign exchange contracts at June 30, 2016 and December 31, 2015 (in millions):

| Buy                       | Notional<br>Amount in Buy<br>Currency | Sell          | Maturity       | Notional<br>Amount in U.S.<br>Dollars | Fair Value of<br>Assets | Fair Value of<br>Liabilities |
|---------------------------|---------------------------------------|---------------|----------------|---------------------------------------|-------------------------|------------------------------|
| <b>June 30, 2016:</b>     |                                       |               |                |                                       |                         |                              |
| Euro                      | 26.2                                  | U.S. Dollars  | July 2016      | \$ 29.7                               | \$ —                    | \$ 0.8                       |
| Swiss Francs              | 5.8                                   | U.S. Dollars  | July 2016      | 6.0                                   | —                       | 0.1                          |
| U.S. Dollars              | 6.0                                   | Israel Shekel | July 2016      | 6.0                                   | 0.2                     | —                            |
| Swiss Francs              | 1.4                                   | Canada Dollar | July 2016      | 1.5                                   | —                       | —                            |
| Canada Dollar             | 1.9                                   | Swiss Francs  | July 2016      | 1.4                                   | —                       | —                            |
| Euro                      | 1.4                                   | Polish Zloty  | September 2016 | 1.5                                   | —                       | —                            |
|                           |                                       |               |                | <u>\$ 46.1</u>                        | <u>\$ 0.2</u>           | <u>\$ 0.9</u>                |
| <b>December 31, 2015:</b> |                                       |               |                |                                       |                         |                              |
| Euro                      | 21.1                                  | U.S. Dollars  | January 2016   | \$ 24.2                               | \$ —                    | \$ 1.2                       |
| Swiss Francs              | 5.9                                   | U.S. Dollars  | April 2016     | 6.0                                   | —                       | 0.1                          |
| U.S. Dollars              | 6.0                                   | Israel Shekel | April 2016     | 6.0                                   | —                       | —                            |
|                           |                                       |               |                | <u>\$ 36.2</u>                        | <u>\$ —</u>             | <u>\$ 1.3</u>                |

In addition, the Company periodically enters into purchase and sales contracts denominated in currencies other than the functional currency of the parties to the transaction. The Company accounts for these transactions by separately valuing the “embedded derivative” component of these contracts. Contracts denominated in currencies other than the functional currency of the transacting parties amounted to \$81.2 million for the delivery of products and \$3.4 million for the purchase of products at June 30, 2016 and \$59.0 million for the delivery of products and \$4.1 million for the purchase of products at December 31, 2015. The changes in the fair value of these embedded derivatives are recorded as foreign currency exchange gains/losses within interest and other income (expense), net in the unaudited condensed consolidated statements of income and comprehensive income.

### ***Commodity Price Risk Management***

The Company has an arrangement with a customer under which it has a firm commitment to deliver copper based superconductors at a fixed price. In order to minimize the volatility that fluctuations in the price of copper have on the Company’s sales of these superconductors, the Company enters into commodity hedge contracts. At June 30, 2016 and December 31, 2015, the Company had fixed price commodity contracts with notional amounts aggregating \$0.9 million and \$2.0 million, respectively. The changes in the fair value of these commodity contracts are recorded within interest and other income (expense), net in the unaudited condensed consolidated statements of income and comprehensive income.

The fair value of the derivative instruments described above is recorded in the unaudited condensed consolidated balance sheets for the periods as follows (in millions):

|                                                         | Balance Sheet Location    | June 30,<br>2016 | December 31,<br>2015 |
|---------------------------------------------------------|---------------------------|------------------|----------------------|
| <b>Derivative assets:</b>                               |                           |                  |                      |
| Foreign exchange contracts                              | Other current assets      | \$ 0.2           | \$ —                 |
| Embedded derivatives in purchase and delivery contracts | Other current assets      | 0.1              | 0.5                  |
| <b>Derivative liabilities:</b>                          |                           |                  |                      |
| Foreign exchange contracts                              | Other current liabilities | \$ 0.9           | \$ 1.3               |
| Embedded derivatives in purchase and delivery contracts | Other current liabilities | 0.4              | 0.5                  |
| Fixed price commodity contracts                         | Other current liabilities | 0.2              | 0.4                  |

The impact on net income of unrealized gains and losses resulting from changes in the fair value of derivative instruments not designated as hedging instruments are as follows (in millions):

|                                                         | Three Months Ended June 30, |         | Six Months Ended June 30, |        |
|---------------------------------------------------------|-----------------------------|---------|---------------------------|--------|
|                                                         | 2016                        | 2015    | 2016                      | 2015   |
| Foreign exchange contracts                              | \$ (1.6)                    | \$ 10.7 | \$ 0.6                    | \$ 8.0 |
| Embedded derivatives in purchase and delivery contracts | —                           | (0.1)   | (0.3)                     | 0.2    |
| Fixed price commodity contracts                         | 0.1                         | (0.1)   | 0.2                       | (0.1)  |
| Other income (expense), net                             | \$ (1.5)                    | \$ 10.5 | \$ 0.5                    | \$ 8.1 |

The amounts related to derivative instruments not designated as hedging instruments are recorded within interest and other income (expense), net in the unaudited condensed consolidated statements of income and comprehensive income.

## 9. Provision for Income Taxes

The Company accounts for income taxes using the asset and liability approach by recognizing deferred tax assets and liabilities for the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized. In addition, the Company accounts for uncertain tax positions that have reached a minimum recognition threshold.

The income tax provision for the three months ended June 30, 2016 and 2015 was \$3.0 million and \$2.3 million, respectively, representing effective tax rates of 16.9% and 9.1%, respectively. The income tax provision for the six months ended June 30, 2016 and 2015 was \$7.8 million and \$7.1 million, respectively, representing effective tax rates of 16.9% and 19.1%, respectively. The increase in our effective tax rate for the three months ended June 30, 2016, compared to the same period in 2015, was primarily caused by changes in the expected mix of earnings among tax jurisdictions. The decrease in our effective tax rate for the six months ended June 30, 2016, compared to the same period in 2015, was primarily caused by the recognition of previously unrecognized tax benefits due to the closure of certain tax audits and changes in the expected mix of earnings among tax jurisdictions. The Company's effective tax rate may change over time as the amount or mix of income and taxes changes among the jurisdictions in which the Company is subject to tax.

As of June 30, 2016 and December 31, 2015, the Company has unrecognized tax benefits, excluding penalties and interest, of approximately \$10.9 million and \$26.9 million, respectively, of which \$10.4 million and \$13.0 million, if recognized, would result in a reduction of the Company's effective tax rate. The Company recognizes penalties and interest related to unrecognized tax benefits in the provision for income taxes. As of June 30, 2016 and December 31, 2015, approximately \$1.5 million and \$4.7 million, respectively, of accrued interest and penalties related to uncertain tax positions was included in other long-term liabilities on the unaudited condensed consolidated balance sheets. Penalties and interest related to unrecognized tax benefits of \$1.0 million and \$0.3 million were recorded in the provision for income taxes during the three months ended June 30, 2016 and 2015, respectively, and \$3.3 million and \$1.1 million during the six months ended June 30, 2016 and 2015, respectively.

The Company files tax returns in the United States, which include federal, state and local jurisdictions, and many foreign jurisdictions with varying statutes of limitations. The Company considers Germany, the United States and Switzerland to be its significant tax jurisdictions. The tax years 2009 to 2015 are open tax years in Germany and Switzerland. Tax years 2011 to 2015 remain open for examination in the United States.

The Company asserts that its foreign earnings, with the exception of its foreign earnings that have been previously taxed by the U.S., are indefinitely reinvested. The Company regularly evaluates its assertion that its foreign earnings are indefinitely reinvested. If the cash, cash equivalents and short-term investments held by the Company's foreign subsidiaries are needed to fund operations in the U.S., or the Company otherwise elects to repatriate the unremitted earnings of its foreign subsidiaries in the form of dividends or otherwise, or if the shares of the subsidiaries were sold or transferred, the Company would likely be subject to additional U.S. income taxes, net of the impact of any available tax credits, which could result in a higher effective tax rate in the future.

## **10. Commitments and Contingencies**

### ***Legal***

Lawsuits, claims and proceedings of a nature considered normal to its businesses may be pending from time to time against the Company. The Company believes the outcome of these proceedings, individually and in the aggregate, will not have a material impact on the Company's financial position or results of operations. As of June 30, 2016 and December 31, 2015, accruals recorded for such potential contingencies were immaterial to the unaudited condensed consolidated financial statements.

The Company understands that the Korea Fair Trade Commission ("KFTC") is conducting an investigation into improper bidding by Bruker Korea Co., Ltd. and several other companies in connection with bids for sales of X-ray systems in 2010 and 2012. Three of the bids under investigation involved Bruker Korea. The Company is cooperating fully with the KFTC regarding this matter. The potential range of penalties which may arise as a result of any proceedings which may be brought by the KFTC or other Korean government agencies against the Company or its subsidiaries operating in Korea involving this matter could include the imposition of a civil and/or criminal fine and a suspension of all or a portion of the Company's operations from bidding for or conducting sales to Korean governmental agencies for a period of time. At this time the Company cannot reasonably assess the timing or outcome of these matters or their effect, if any, on the Company's business or results of operations. Sales to customers in Korea were approximately 2% of the Company's revenue for the year ended December 31, 2015.

### ***Letters of Credit and Guarantees***

At June 30, 2016 and December 31, 2015, the Company had bank guarantees of \$130.3 million and \$137.7 million, respectively, related primarily to customer advances. These arrangements guarantee the refund of advance payments received from customers in the event that the merchandise is not delivered or warranty obligations are not fulfilled in compliance with the terms of the contract. These guarantees affect the availability of the Company's lines of credit.

## **11. Shareholders' Equity**

### ***Share Repurchase Program***

In November 2015, the Company's Board of Directors suspended the Company's previously announced Anti-Dilutive Repurchase Program until January 1, 2017 and approved an additional share repurchase program (the "Repurchase Program") under which repurchases of common stock up to \$225.0 million may occur from time to time, in amounts, at prices, and at such times as the Company deems appropriate, subject to market conditions, legal requirements and other considerations. A total of 1,200,000 shares were repurchased at an aggregate cost of \$34.5 million in the three months ended June 30, 2016 and 4,577,858 shares were repurchased at an aggregate cost of \$117.6 million in the six months ended June 30, 2016. Since inception of the Repurchase Program through June 30, 2016, 7,414,900 shares were repurchased at an aggregate cost of \$182.6 million. The remaining authorization under the Repurchase Program is \$42.4 million. Any future repurchases will be funded from cash on hand, future cash flows from operations and available borrowings under the revolving credit facility.

The repurchased shares are reflected within Treasury stock in the accompanying unaudited condensed consolidated balance sheet at June 30, 2016 and December 31, 2015.

### ***Cash Dividends on Shares of Common Stock***

On February 22, 2016, the Company announced the establishment of a dividend policy and the declaration by its Board of Directors of an initial quarterly cash dividend in the amount of \$0.04 per share of the Company's issued and outstanding common stock. Dividends were paid on March 24, 2016 to shareholders of record as of March 4, 2016 and on June 24, 2016 to shareholders of record as of June 6, 2016, in each case for an aggregate cost of \$6.5 million. Under the dividend policy, the Company will target a cash dividend to the Company's shareholders in the amount of \$0.16 per share per annum, payable in equal quarterly installments. Subsequent dividend declarations and the establishment of record and payment dates for such future dividend payments, if any, are subject to the Board of Directors' continuing determination that the dividend policy is in the best interests of the Company's shareholders. The dividend policy may be suspended or cancelled at the discretion of the Board of Directors at any time.

### ***Accumulated Other Comprehensive Income (Loss)***

Comprehensive income (loss) refers to revenues, expenses, gains and losses that under U.S. GAAP are included in other comprehensive income (loss), but excluded from net income as these amounts are recorded directly as an adjustment to shareholders' equity, net of tax. The Company's other comprehensive income (loss) is composed primarily of foreign currency translation adjustments and changes in the funded status of defined benefit pension plans. The following is a summary of comprehensive income (loss) (in millions):

|                                                                     | <b>Three Months Ended June 30,</b> |                | <b>Six Months Ended June 30,</b> |               |
|---------------------------------------------------------------------|------------------------------------|----------------|----------------------------------|---------------|
|                                                                     | <b>2016</b>                        | <b>2015</b>    | <b>2016</b>                      | <b>2015</b>   |
| Consolidated net income                                             | \$ 14.8                            | \$ 23.1        | \$ 38.4                          | \$ 30.0       |
| Foreign currency translation adjustments                            | (18.6)                             | 35.8           | 15.0                             | (37.1)        |
| Pension liability adjustments                                       | 1.6                                | 0.5            | 0.6                              | 8.8           |
| Net comprehensive income                                            | (2.2)                              | 59.4           | 54.0                             | 1.7           |
| Less: Comprehensive income attributable to noncontrolling interests | 0.1                                | 0.8            | 0.3                              | 1.2           |
| Comprehensive income attributable to Bruker Corporation             | <u>\$ (2.3)</u>                    | <u>\$ 58.6</u> | <u>\$ 53.7</u>                   | <u>\$ 0.5</u> |

The following is a summary of the components of accumulated other comprehensive income (loss), net of tax, at June 30, 2016 (in millions):

|                                                                | <b>Foreign<br/>Currency<br/>Translation</b> | <b>Pension<br/>Liability<br/>Adjustment</b> | <b>Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</b> |
|----------------------------------------------------------------|---------------------------------------------|---------------------------------------------|------------------------------------------------------------------|
| Balance at December 31, 2015                                   | \$ 3.2                                      | \$ (47.4)                                   | \$ (44.2)                                                        |
| Other comprehensive income (loss) before reclassifications     | 14.9                                        | (1.0)                                       | 13.9                                                             |
| Realized loss on reclassification, net of tax of \$0.3 million | —                                           | 1.6                                         | 1.6                                                              |
| Net current period other comprehensive income                  | 14.9                                        | 0.6                                         | 15.5                                                             |
| Balance at June 30, 2016                                       | <u>\$ 18.1</u>                              | <u>\$ (46.8)</u>                            | <u>\$ (28.7)</u>                                                 |

## **12. Noncontrolling Interests**

Noncontrolling interests represent the minority shareholders' proportionate share of the Company's majority owned subsidiaries. The following table sets forth the changes in noncontrolling interests (in millions):

|                                          | <b>Three Months Ended June 30,</b> |               | <b>Six Months Ended June 30,</b> |               |
|------------------------------------------|------------------------------------|---------------|----------------------------------|---------------|
|                                          | <b>2016</b>                        | <b>2015</b>   | <b>2016</b>                      | <b>2015</b>   |
| Balance at beginning of period           | \$ 7.0                             | \$ 5.8        | \$ 6.8                           | \$ 5.8        |
| Net income                               | 0.3                                | 1.2           | 0.3                              | 1.6           |
| Foreign currency translation adjustments | (0.2)                              | 0.1           | —                                | (0.3)         |
| Other                                    | —                                  | (0.5)         | —                                | (0.5)         |
| Balance at end of period                 | <u>\$ 7.1</u>                      | <u>\$ 6.6</u> | <u>\$ 7.1</u>                    | <u>\$ 6.6</u> |

## **13. Other Charges, Net**

The components of other charges, net were as follows (in millions):

|                                             | Three Months Ended June 30, |        | Six Months Ended June 30, |         |
|---------------------------------------------|-----------------------------|--------|---------------------------|---------|
|                                             | 2016                        | 2015   | 2016                      | 2015    |
| Information technology transformation costs | \$ 1.7                      | \$ 1.9 | \$ 3.9                    | \$ 3.6  |
| Restructuring charges                       | 1.8                         | 1.0    | 3.6                       | 2.3     |
| Pension settlement charge                   | —                           | —      | —                         | 10.2    |
| Acquisition-related charges (benefits)      | 7.9                         | (2.9)  | 7.9                       | (2.9)   |
| Long-lived asset impairments                | 0.6                         | 1.8    | 0.6                       | 1.8     |
| Other charges, net                          | \$ 12.0                     | \$ 1.8 | \$ 16.0                   | \$ 15.0 |

In recent years, the Company has been undertaking productivity improvement initiatives in an effort to better optimize its operations. These restructuring initiatives have included the divestiture of certain non-core businesses, outsourcing of various manufacturing activities, transferring or ceasing operations at certain facilities, and an overall right-sizing within the Company based on the current business environment.

The Company recorded total restructuring charges during the three months ended June 30, 2016 of \$3.7 million related to these initiatives, all within the BSI Segment. These charges consisted of \$0.9 million of inventory provisions for excess inventory, \$1.0 million of severance costs and \$1.8 million of exit related costs, such as professional service and facility exit charges. During the three months ended June 30, 2016, the Company recorded restructuring charges of \$1.9 million as a component of cost of revenue and \$1.8 million as a component of other charges, net in the accompanying unaudited condensed consolidated statements of income and comprehensive income. The Company recorded total restructuring charges during the six months ended June 30, 2016 of \$7.5 million related to these initiatives, all within the BSI Segment. These charges consisted of \$1.1 million of inventory provisions for excess inventory, \$3.3 million of severance costs and \$3.1 million of exit related costs, such as professional service and facility exit charges. During the six months ended June 30, 2016, the Company recorded restructuring charges of \$3.9 million as a component of cost of revenue and \$3.6 million as a component of other charges, net in the accompanying unaudited condensed consolidated statements of income and comprehensive income.

The Company commenced a restructuring initiative in 2015 within the Bruker BioSpin Group, which was developed as a result of a revenue decline that occurred during the second half of 2014 and continued during the first half of 2015. This initiative was intended to improve Bruker BioSpin Group's operating results. Restructuring actions resulted in a reduction of employee headcount within the Bruker BioSpin Group of approximately 9%. Included in the total restructuring charges discussed above are restructuring expenses related to this initiative recorded during the six months ended June 30, 2016 of \$3.3 million of severance and exit costs, of which \$2.2 million was recorded as a component of cost of revenue and \$1.1 million as a component of other charges, net in the accompanying unaudited condensed consolidated statements of income and comprehensive income. The restructuring initiative also included the closure and consolidation of a Bruker BioSpin Group manufacturing facility. From inception of the restructuring initiative in the second quarter of 2015, cumulative restructuring expenses and other one-time charges recorded have been \$19.5 million, consisting of \$4.2 million of inventory write-downs and asset impairments and \$15.3 million of severance and exit costs. As of June 30, 2016, expenses incurred under the restructuring initiative were substantially complete.

The following table sets forth the changes in restructuring reserves for the six months ended June 30, 2016 (in millions):

|                                                         | Total   | Severance | Exit Costs | Provisions for Excess Inventory |
|---------------------------------------------------------|---------|-----------|------------|---------------------------------|
| Balance at December 31, 2015                            | \$ 23.1 | \$ 10.3   | \$ 2.4     | \$ 10.4                         |
| Restructuring charges                                   | 7.5     | 3.3       | 3.1        | 1.1                             |
| Cash payments                                           | (12.7)  | (9.5)     | (2.3)      | (0.9)                           |
| Other, non-cash adjustments and foreign currency effect | (3.0)   | —         | (0.9)      | (2.1)                           |
| Balance at June 30, 2016                                | \$ 14.9 | \$ 4.1    | \$ 2.3     | \$ 8.5                          |

#### 14. Interest and Other Income (Expense), Net

The components of interest and other income (expense), net, were as follows (in millions):

|                                                          | Three Months Ended June 30, |          | Six Months Ended June 30, |          |
|----------------------------------------------------------|-----------------------------|----------|---------------------------|----------|
|                                                          | 2016                        | 2015     | 2016                      | 2015     |
| Interest expense, net                                    | \$ (2.9)                    | \$ (3.1) | \$ (6.0)                  | \$ (6.2) |
| Exchange gains (losses) on foreign currency transactions | 0.7                         | (2.9)    | (1.6)                     | (3.3)    |
| Loss on disposal of product line                         | —                           | (0.2)    | —                         | (0.2)    |
| Other                                                    | (0.4)                       | —        | (0.6)                     | —        |
| Interest and other income (expense), net                 | \$ (2.6)                    | \$ (6.2) | \$ (8.2)                  | \$ (9.7) |

## 15. Business Segment Information

The Company has two reportable segments, BSI and BEST, as discussed in Note 1 to the unaudited condensed consolidated financial statements.

Revenue and operating income by reportable segment are presented below (in millions):

|                                       | Three Months Ended June 30, |          | Six Months Ended June 30, |          |
|---------------------------------------|-----------------------------|----------|---------------------------|----------|
|                                       | 2016                        | 2015     | 2016                      | 2015     |
| Revenue:                              |                             |          |                           |          |
| BSI                                   | \$ 345.7                    | \$ 366.2 | \$ 696.1                  | \$ 693.7 |
| BEST                                  | 28.5                        | 30.8     | 55.7                      | 58.3     |
| Eliminations (a)                      | (2.5)                       | (1.0)    | (4.7)                     | (2.5)    |
| Total revenue                         | \$ 371.7                    | \$ 396.0 | \$ 747.1                  | \$ 749.5 |
| Operating Income                      |                             |          |                           |          |
| BSI                                   | \$ 18.9                     | \$ 28.7  | \$ 51.9                   | \$ 42.4  |
| BEST                                  | 1.4                         | 2.6      | 1.4                       | 3.6      |
| Corporate, eliminations and other (b) | 0.1                         | 0.3      | 1.1                       | 0.8      |
| Total operating income                | \$ 20.4                     | \$ 31.6  | \$ 54.4                   | \$ 46.8  |

(a) Represents product and service revenue between reportable segments.

(b) Represents corporate costs and eliminations not allocated to the reportable segments.

Total assets by reportable segment are as follows (in millions):

|                            | June 30,<br>2016 | December 31,<br>2015 |
|----------------------------|------------------|----------------------|
| Assets:                    |                  |                      |
| BSI                        | \$ 1,704.2       | \$ 1,714.4           |
| BEST                       | 19.3             | 79.1                 |
| Eliminations and other (a) | (3.0)            | (63.5)               |
| Total assets               | \$ 1,720.5       | \$ 1,730.0           |

(a) Assets not allocated to the reportable segments and eliminations of intercompany transactions.

## 16. Recent Accounting Pronouncements

In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-09, *Stock Compensation - Improvements to Employee Share-Based Payment Accounting*. The new standard simplifies accounting for share-based payment transactions, including income tax consequences and the classification of the tax impact on the statement of cash flows. The new standard is effective as of January 1, 2017, and early adoption is permitted. The Company is evaluating the provisions of this statement, including which period to adopt, and has not determined what impact the adoption of ASU No. 2016-09 will have on the Company's unaudited condensed consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, *Leases*. The new standard provides guidance on the recognition, measurement, presentation, and disclosure of leases. The new standard supersedes present U.S. GAAP guidance on leases and requires substantially all leases to be reported on the balance sheet as right-of-use assets and lease liabilities, as well as additional disclosures. The new standard is effective as of January 1, 2019, and early adoption is permitted. The Company is evaluating the provisions of this statement, including which period to adopt, and has not determined what impact the adoption

of ASU No. 2016-02 will have on the Company's unaudited condensed consolidated financial statements.

In July 2015, the FASB issued ASU No. 2015-11, *Simplifying the Measurement of Inventory*. The new guidance eliminates the measurement of inventory at market value, and inventory will now be measured at the lower of cost and net realizable value. The ASU defines net realizable value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. No other changes were made to the current guidance on inventory measurement. ASU No. 2015-11 is effective for interim and annual periods beginning after December 15, 2016. Early application is permitted and should be applied prospectively. The Company is evaluating the provisions of this statement, including which period to adopt, and has not determined what impact the adoption of ASU No. 2015-11 will have on the Company's unaudited condensed consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, *Revenue from Contracts with Customers*, which supersedes the revenue recognition requirements under ASC Topic 605. The new guidance was the result of a joint project between the FASB and the International Accounting Standards Board to clarify the principles for recognizing revenue and to develop common revenue standards for GAAP and International Financial Reporting Standards. The core principle of the new guidance is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB elected to defer the effective date of ASU No. 2014-09 by one year to annual periods beginning after December 15, 2017, with early application permitted as of the previous effective date of December 15, 2016. The Company is currently assessing the impact the new guidance may have on its unaudited condensed consolidated financial statements upon adoption.

## **ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

The following discussion of our financial condition and results of operations should be read in conjunction with our interim unaudited condensed consolidated financial statements and the notes to those statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q, and in conjunction with the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2015.

Statements contained in Management's Discussion and Analysis of Financial Condition and Results of Operations, which express that we "believe," "anticipate," "plan," "expect," "seek," "estimate," or "should," as well as other statements which are not historical fact, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from those set forth in forward-looking statements. Certain factors that might cause such a difference are discussed in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2015.

Although our unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP), we believe describing revenue and expenses, excluding the effects of foreign currency, acquisitions and divestitures, as well as certain other charges, net, provides meaningful supplemental information regarding our performance. Specifically, management believes that free cash flow and organic revenue, both non-GAAP financial measures, as well as non-GAAP gross margin and non-GAAP operating margin, provide relevant and useful information which is widely used by analysts, investors and competitors in our industry, as well as by our management, in assessing both consolidated and business unit performance. We use non-GAAP financial measures to evaluate our period-over-period operating performance because our management believes this provides a more comparable measure of our continuing business as it adjusts for certain items that are not reflective of the underlying performance of our business. These measures may also be useful to investors in evaluating the underlying operating performance of our business.

These non-GAAP financial measures are not in accordance with, nor are they a substitute for, the comparable GAAP financial measures and are intended to supplement our financial results that are prepared in accordance with GAAP. We regularly use non-GAAP financial measures internally to understand, manage, and evaluate our business results and make operating decisions. We also measure our employees and compensate them, in part, based on such non-GAAP measures. The calculation of these non-GAAP financial measures may differ from the calculation of similarly titled financial measures presented by other companies and, therefore, may not be comparable among companies.

## OVERVIEW

We are organized into four operating segments, as further described in Note 1 in the unaudited condensed consolidated financial statements and in our Annual Report on Form 10-K for the year ended December 31, 2015: the Bruker BioSpin Group, the Bruker CALID Group, the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

For the three months ended June 30, 2016, our revenue decreased by \$24.3 million, or 6.1%, to \$371.7 million, compared to \$396.0 million for the comparable period in 2015. The impact of changes in foreign currency and a recent acquisition in our Bruker Nano Group caused a net increase of \$12.0 million, or 3.1%. Excluding these items, organic revenue, a non-GAAP measure, decreased 9.2%, primarily as a result of delays in European academic funding, weaker industrial markets and lower MALDI Biotyper sales in China and the U.S.

For the six months ended June 30, 2016, our revenue decreased by \$2.4 million, or 0.3%, to \$747.1 million, compared to \$749.5 million for the comparable period in 2015. The impact of changes in foreign currency and a recent acquisition in our Bruker Nano Group caused a net increase of \$14.1 million, or 1.9%. Excluding these items, organic revenue, a non-GAAP measure, decreased 2.2%. The decrease was primarily caused by continued weak demand within our Bruker Nano Group industrial market segments, delays in European academic funding and lower MALDI Biotyper sales in China and the U.S. These decreases were partially offset by increased revenues within the Bruker BioSpin Group due to higher volume, increased pricing and the recognition of revenues from the sale of the first shielded ultra-high field gigahertz nuclear magnetic resonance system as well as increased sales of Raman, near infrared and remote sensing products within the Bruker CALID Group

Our gross profit margin increased to 45.8% from 42.8% during the three months ended June 30, 2016 and 2015, respectively, and to 45.1% from 44.0% during the six months ended June 30, 2016 and 2015, respectively. The increases in gross margin percentages were primarily caused by operating cost improvements as a result of recent restructuring and outsourcing actions, the impact of pricing increases and a favorable product mix within the Bruker BioSpin Group and the impact of a recent acquisition within the Bruker Nano Group. The beneficial impact of these items was offset in part by weakness in Bruker Nano Group industrial market segments, delays in European academic funding within our Bruker CALID and Bruker Nano Groups, and a decline in the BEST Segment resulting from the completion of certain high margin orders in the comparable prior period.

Operating expenses during the three months ended June 30, 2016 increased by approximately \$11.9 million compared to the same period in the prior year, primarily as a result of an increase in contingent consideration related to a recent acquisition in our Bruker Nano Group based upon an increase in forecasted revenue levels for the acquired business for the remainder of 2016 offset in part by operational improvements and restructuring actions. Operating expenses during the six months ended June 30, 2016 decreased by approximately \$0.3 million compared to the prior year, caused primarily by our operational improvements and restructuring actions offset by the increase in contingent consideration.

Earnings per share decreased \$0.04 to \$0.09 per diluted share for the three months ended June 30, 2016 when compared to the same period in 2015, primarily as a result of an increase in contingent consideration noted above partially offset by the favorable impact of our share repurchase program. Earnings per share increased \$0.06 to \$0.23 per diluted share for the six months ended June 30, 2016 when compared to the same period in 2015. The increase in earnings per diluted share for the six months ended June 30, 2016 was primarily the result of increased gross profit margins, operational improvements and restructuring actions, the impact of a recent acquisition within our Bruker Nano Group and the impact of our share repurchase program.

Operating cash flow for the six months ended June 30, 2016 was a source of cash of \$4.1 million. We believe free cash flow, a non-GAAP financial measure which we define as net cash provided by operating activities less purchases of property, plant and equipment, is a useful measure to evaluate our business as it indicates the amount of cash generated after additions to property, plant, and equipment that is available for, among other things, strategic acquisitions, investments in our business, and repayment of debt. In the six months ended June 30, 2016, our free cash flow was negative \$13.1 million, calculated as follows:

|                                                  |    |        |
|--------------------------------------------------|----|--------|
| Net cash provided by operating activities        | \$ | 4.1    |
| Less: Purchases of property, plant and equipment |    | 17.2   |
| Free Cash Flow                                   | \$ | (13.1) |

Our negative free cash flow was primarily caused by an increase in inventory purchases needed for production in the second half of 2016, the timing of customer advances received and installation and acceptance of the related systems, and tax payments, including withholding tax payments made in the first quarter of 2016 related to the Company's 2015 European cash repatriation. These uses of cash were partially offset by a decrease in accounts receivable resulting from reduced revenue levels and higher than normal collections in the fourth quarter of 2015.

In November 2015, our Board of Directors suspended the previously announced Anti-Dilutive Repurchase Program until January 1, 2017 and approved an additional share repurchase program (the “Repurchase Program”) under which repurchases of common stock up to \$225.0 million may occur from time to time, in amounts, at prices, and at such times as we deem appropriate, subject to market conditions, legal requirements and other considerations. A total of 1,200,000 shares were repurchased at an aggregate cost of \$34.5 million in the three months ended June 30, 2016, 4,577,858 shares were repurchased as an aggregate cost of \$117.6 million in the six months ended June 30, 2016 and 7,414,900 shares were repurchased at an aggregate cost of \$182.6 million from the inception of the Repurchase Program through June 30, 2016. The remaining authorization under the Repurchase Program is \$42.4 million. Any additional repurchases will be funded from cash on hand, future cash flows from operations and available borrowings under the revolving credit facility.

On February 22, 2016, we announced the establishment of a dividend policy and the declaration by our Board of Directors of an initial quarterly cash dividend in the amount of \$0.04 per share of our issued and outstanding common stock. An initial dividend was paid on March 24, 2016 to shareholders of record as of March 4, 2016 for a total cost of \$6.5 million and a subsequent dividend was paid on June 24, 2016 to shareholders of record as of June 6, 2016 for a total cost of \$6.5 million. Under the dividend policy, we will target a cash dividend to our shareholders in the amount of \$0.16 per share per annum, payable in equal quarterly installments. Subsequent dividend declarations and the establishment of record and payment dates for such future dividend payments, if any, are subject to the Board of Directors’ continuing determination that the dividend policy is in the best interests of our shareholders. The dividend policy may be suspended or cancelled at the discretion of the Board of Directors at any time.

As previously disclosed, we have taken restructuring measures as a result of the revenue decline that occurred during the second half of 2014 and continued during the first half of 2015 within Bruker BioSpin Group. This included a restructuring initiative that commenced during 2015 that reduced employee headcount by approximately 9% within our Bruker BioSpin Group. Income from operations included restructuring costs of \$3.3 million for the six months ended June 30, 2016 related to this initiative. Total restructuring and other one-time charges, incurred in 2015 and continuing into 2016, were \$19.5 million of which \$15.3 million related to employee separation and facility exit costs and \$4.2 million related to estimated inventory write-downs and asset impairments. As of June 30, 2016, expenses incurred under this restructuring initiative were substantially complete and we expect to generate approximately \$10 million in annualized savings as a result of this initiative.

As a result of demand weakness we expect for the remainder of 2016, particularly in Europe, we intend to accelerate certain planned operational restructuring initiatives, as well as take business right-sizing measures. These actions are expected to include further facility consolidation and production outsourcing, product line consolidation, and other cost reduction initiatives. We expect to finalize these plans in the third quarter of 2016. While we expect most of the savings from these actions to increase our profitability, some will be reinvested into new sales, marketing, and product management capabilities and our strategic growth initiatives.

We can experience quarter-to-quarter fluctuations in our operating results as a result of various factors, some of which are outside our control, such as:

- the timing of governmental stimulus programs and academic research budgets;
- the time it takes between the date customer orders and deposits are received, systems are shipped and accepted by our customers and full payment is received;
- the time it takes for customers to construct or prepare their facilities for our products; and
- the time required to obtain governmental licenses.

These factors have in the past affected the amount and timing of revenue recognized on sales of our products and receipt of related payments and will continue to do so in the future. Accordingly, our operating results in any particular quarter may not necessarily be an indication of any future quarter’s operating performance.

## **CRITICAL ACCOUNTING POLICIES AND ESTIMATES**

This discussion and analysis of our financial condition and results of operations is based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States of America. The preparation of these financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. We base our estimates and

judgments on our historical experience, current market and economic conditions, industry trends, and other assumptions that we believe are reasonable and form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

We believe the following critical accounting policies and estimates to be both those most important to the portrayal of our financial position and results of operations and those that require the most estimation and subjective judgment:

- Revenue recognition;
- Income taxes;
- Inventories;
- Goodwill, other intangible assets and other long-lived assets; and
- Employee benefit plan assumptions.

For a further discussion of our critical accounting policies, please refer to our Annual Report on Form 10-K for the year ended December 31, 2015. There were no significant changes to our critical accounting policies for the three or six months ended June 30, 2016.

## **RESULTS OF OPERATIONS**

*Three Months Ended June 30, 2016 compared to the Three Months Ended June 30, 2015*

### ***Consolidated Results***

The following table presents our results for the three months ended June 30, 2016 and 2015 (dollars in millions, except per share data):

|                                                                                     | Three Months Ended June 30, |          |
|-------------------------------------------------------------------------------------|-----------------------------|----------|
|                                                                                     | 2016                        | 2015     |
| Product revenue                                                                     | \$ 305.6                    | \$ 336.2 |
| Service revenue                                                                     | 63.5                        | 58.2     |
| Other revenue                                                                       | 2.6                         | 1.6      |
| Total revenue                                                                       | 371.7                       | 396.0    |
| Cost of product revenue                                                             | 162.3                       | 191.5    |
| Cost of service revenue                                                             | 38.0                        | 35.0     |
| Cost of other revenue                                                               | 1.3                         | 0.1      |
| Total cost of revenue                                                               | 201.6                       | 226.6    |
| Gross profit                                                                        | 170.1                       | 169.4    |
| Operating expenses:                                                                 |                             |          |
| Selling, general and administrative                                                 | 100.9                       | 98.5     |
| Research and development                                                            | 36.8                        | 37.5     |
| Other charges, net                                                                  | 12.0                        | 1.8      |
| Total operating expenses                                                            | 149.7                       | 137.8    |
| Operating income                                                                    | 20.4                        | 31.6     |
| Interest and other income (expense), net                                            | (2.6)                       | (6.2)    |
| Income before income taxes and noncontrolling interest in consolidated subsidiaries | 17.8                        | 25.4     |
| Income tax provision                                                                | 3.0                         | 2.3      |
| Consolidated net income                                                             | 14.8                        | 23.1     |
| Net income attributable to noncontrolling interest in consolidated subsidiaries     | 0.3                         | 1.2      |
| Net income attributable to Bruker Corporation                                       | \$ 14.5                     | \$ 21.9  |
| Net income per common share attributable to Bruker Corporation shareholders:        |                             |          |
| Basic and diluted                                                                   | \$ 0.09                     | \$ 0.13  |
| Weighted average common shares outstanding:                                         |                             |          |
| Basic                                                                               | 161.4                       | 168.3    |
| Diluted                                                                             | 162.4                       | 169.7    |

### Revenue

For the three months ended June 30, 2016, our revenue decreased \$24.3 million, or 6.1%, to \$371.7 million, compared to \$396.0 million for the comparable period in 2015. Included in revenue was an increase of approximately \$12.0 million attributable to a recent acquisition within the Bruker Nano Group and no impact from foreign currency translation. Excluding the effects of our recent acquisition, our organic revenue, a non-GAAP measure, decreased by \$36.3 million, or 9.2%.

BSI Segment revenue decreased by \$20.5 million, or 5.6%, to \$345.7 million for the three months ended June 30, 2016, compared to \$366.2 million for the three months ended June 30, 2015. BEST Segment revenue decreased by \$2.3 million, or 7.5%, to \$28.5 million for the three months ended June 30, 2016, compared to \$30.8 million for the three months ended June 30, 2015.

Please see the Segment Results section later in this discussion for additional information regarding our revenue.

### Gross Profit

Gross profit for the three months ended June 30, 2016 was \$170.1 million, or 45.8% of revenue, compared to \$169.4 million, or 42.8% of revenue, for the three months ended June 30, 2015. Included in gross profit were various charges for

amortization of acquisition-related intangible assets and other acquisition-related costs and restructuring costs totaling \$6.8 million and \$9.0 million for the three months ended June 30, 2016 and 2015, respectively. Excluding these charges, our non-GAAP gross profit margin for the three months ended June 30, 2016 and 2015 was 47.6% and 45.1%, respectively. The increase in our gross profit margins was caused primarily by operating cost improvements as a result of recent restructuring and outsourcing actions, the impact of pricing increases within the Bruker BioSpin Group and the impact of a recent acquisition within the Bruker Nano Group. The favorable effect of these items was partially offset by weakness in Bruker Nano Group industrial market segments, delays in European academic funding within our Bruker CALID and Bruker Nano Group, and a decline in the BEST Segment resulting from the completion of certain high margin orders in the comparable prior period.

#### ***Selling, General and Administrative***

Our selling, general and administrative expenses for the three months ended June 30, 2016 increased to \$100.9 million, or 27.1% of total revenue, from \$98.5 million, or 24.9% of total revenue, for the comparable period in 2015. The increase in selling, general and administrative expenses was attributable to a recent acquisition in the Bruker Nano Group, which was partially offset by the impact of recent operational improvement and restructuring actions. The increase as a percentage of revenue is primarily caused by a decrease in revenue for the three months ended June 30, 2016 as compared to the prior year comparable period.

#### ***Research and Development***

Our research and development expenses for the three months ended June 30, 2016 decreased to \$36.8 million, or 9.9% of total revenue, from \$37.5 million, or 9.5% of total revenue, for the comparable period in 2015. The decrease in dollar value in research and development expenses was primarily attributable to the timing of certain research and development initiatives.

#### ***Other Charges, Net***

Other Charges, net of \$12.0 million recorded for the three months ended June 30, 2016 were all related to the BSI Segment and consisted primarily of \$7.9 million of acquisition-related charges, related primarily to additional contingent consideration recognized for a recent acquisition in the Bruker Nano Group based upon an increase in forecasted revenue levels of the acquired business for the remainder of 2016, \$1.8 million of restructuring costs related to closing facilities and implementing outsourcing and other restructuring initiatives, and \$1.7 million of costs associated with our global information technology (IT) transformation initiative. The IT transformation initiative is a multi-year project aimed at updating and integrating our global enterprise resource planning and human resource information systems.

Other Charges, net of \$1.8 million recorded for the three months ended June 30, 2015 was related almost entirely to the BSI Segment. The charges consisted of \$1.0 million of restructuring costs related to closing facilities and implementing outsourcing and other restructuring initiatives, \$1.8 million of long-lived asset impairments within the Magnetic Resonance division, (\$2.9) million of acquisition-related charges (benefits) primarily caused by the reversal of certain contingent consideration liabilities and \$1.9 million of costs associated with our global IT transformation initiative.

#### ***Operating Income***

Operating income for the three months ended June 30, 2016 was \$20.4 million, resulting in an operating margin of 5.5%, compared to operating income of \$31.6 million, resulting in an operating margin of 8.0%, for the three months ended June 30, 2015. The decrease in operating income was caused primarily by lower revenue and additional contingent consideration recognized related to a recent acquisition within the Bruker Nano Group during the three months ended June 30, 2016 as noted above.

The Company commenced a restructuring initiative in 2015 within the Bruker BioSpin Group, which was developed as a result of a revenue decline that occurred during the second half of 2014 and continued during the first half of 2015 and was intended to improve the Bruker BioSpin Group's operating results. Restructuring actions resulted in a reduction of employee headcount by approximately 9% and included the closure and consolidation of a Bruker BioSpin Group manufacturing facility. Operating income included restructuring costs of \$1.0 million for the three months ended June 30, 2016 related to this initiative.

#### ***Interest and Other Income (Expense), Net***

Interest and other income (expense), net during the three months ended June 30, 2016 was an expense of \$2.6 million

compared to an expense of \$6.2 million for the comparable period of 2015.

During the three months ended June 30, 2016, the major components within interest and other income (expense), net were net interest expense of \$2.9 million and realized and unrealized gains on foreign currency denominated transactions of \$0.7 million. The realized and unrealized gains on foreign currency denominated transactions during the three months ended June 30, 2016 were primarily caused by the fluctuation of the U.S. dollar versus the Euro and other currencies. During the three months ended June 30, 2015, the components within interest and other income (expense), net were net interest expense of \$3.1 million and realized and unrealized losses on foreign currency denominated transactions of \$2.9 million.

### ***Income Tax Provision***

The 2016 and 2015 effective tax rates were estimated using projected annual pre-tax income or loss on a jurisdictional basis. Expected tax benefits, including tax credits and incentives, the impact of changes to valuation allowances, and the effect of jurisdictional differences in statutory tax rates, were also considered in the calculation.

The income tax provision for the three months ended June 30, 2016 and 2015 was \$3.0 million and \$2.3 million, respectively, representing effective tax rates of 16.9% and 9.1%, respectively. The increase in our effective tax rate for the three months ended June 30, 2016, compared to the same period in 2015, was primarily caused by changes in the expected mix of earnings among tax jurisdictions.

### ***Net Income Attributable to Noncontrolling Interests***

Net income attributable to noncontrolling interests for the three months ended June 30, 2016 and 2015 was \$0.3 million and \$1.2 million, respectively. The net income attributable to noncontrolling interests represented the minority shareholders' proportionate share of the net income recorded by our majority-owned subsidiaries.

### ***Net Income Attributable to Bruker Corporation***

Our net income for the three months ended June 30, 2016 was \$14.5 million, or \$0.09 per diluted share, compared to \$21.9 million, or \$0.13 per diluted share, for the comparable period in 2015. The decrease was primarily caused by weaker revenue and the additional contingent consideration recognized related to a recent acquisition in the Bruker Nano Group, partially offset by operating profit improvements as noted above and lower interest and other expenses, net.

### ***Segment Results***

For financial reporting purposes, we aggregate the Bruker BioSpin, Bruker CALID and Bruker Nano operating segments into the Bruker Scientific Instruments (BSI) reportable segment, which represented approximately 93% of the Company's revenues during the three months ended June 30, 2016. This aggregation reflects these operating segments' similar economic characteristics, production processes, service offerings, types and classes of customers, methods of distribution and regulatory environments. Our BEST Segment is our other reportable segment and represents the remainder of our revenues.

### ***Revenue***

The following table presents revenue, change in revenue and revenue growth by reportable segment (dollars in millions):

|                  | Three Months Ended June 30, |                 | Dollar Change    | Percentage Change |
|------------------|-----------------------------|-----------------|------------------|-------------------|
|                  | 2016                        | 2015            |                  |                   |
| BSI              | \$ 345.7                    | \$ 366.2        | \$ (20.5)        | (5.6)%            |
| BEST             | 28.5                        | 30.8            | (2.3)            | (7.5)%            |
| Eliminations (a) | (2.5)                       | (1.0)           | (1.5)            |                   |
|                  | <u>\$ 371.7</u>             | <u>\$ 396.0</u> | <u>\$ (24.3)</u> | (6.1)%            |

(a) Represents product and service revenue between reportable segments.

### **BSI Segment Revenues**

BSI Segment revenue decreased by \$20.5 million, or 5.6%, to \$345.7 million for the three months ended June 30, 2016, compared to \$366.2 million for the three months ended June 30, 2015. Included in revenue was a decrease of approximately \$0.5 million from the impact of foreign currency and an increase of approximately \$12.0 million attributable to a recent acquisition in our Bruker Nano Group. Excluding the effects of foreign currency and our recent acquisition, organic revenue, a non-GAAP measure, decreased by \$32.0 million, or 8.7%, with revenue decline in Europe and Japan driving the majority of the decrease.

The Bruker BioSpin Group revenues decreased during the three months ended June 30, 2016 when compared to the three months ended June 30, 2015, primarily as a result of the timing and recognition of revenue from certain ultra-high field orders which occurred in 2015.

The Bruker CALID Group revenues decreased during the three months ended June 30, 2016 when compared to the three months ended June 30, 2015 primarily due to delays in European academic funding and lower sales of our MALDI Biotyper in China and the U.S.

Excluding the effects of the recent acquisition, the Bruker Nano Group experienced a decrease in revenue primarily caused by continued weaker demand within industrial markets and European academic funding delays.

System revenue and aftermarket revenue as a percentage of total BSI Segment revenue were as follows (dollars in millions):

|                     | Three Months Ended June 30, |                               |                 |                               |
|---------------------|-----------------------------|-------------------------------|-----------------|-------------------------------|
|                     | 2016                        |                               | 2015            |                               |
|                     | Revenue                     | Percentage of Segment Revenue | Revenue         | Percentage of Segment Revenue |
| System revenue      | \$ 241.8                    | 69.9%                         | \$ 269.4        | 73.6%                         |
| Aftermarket revenue | 103.9                       | 30.1%                         | 96.8            | 26.4%                         |
| Total revenue       | <u>\$ 345.7</u>             | <u>100.0%</u>                 | <u>\$ 366.2</u> | <u>100.0%</u>                 |

System revenue in the BSI Segment includes nuclear magnetic resonance systems, magnetic resonance imaging systems, electron paramagnetic imaging systems, mass spectrometry systems, gas chromatography systems, CBRNE detection systems, X-ray systems, spark-optical emission spectroscopy systems, atomic force microscopy systems, stylus and optical metrology systems and molecular spectroscopy systems. Aftermarket revenues in the BSI Segment include accessory sales, consumables, training and services.

### **BEST Segment Revenues**

BEST Segment revenue decreased \$2.3 million, or 7.5%, to \$28.5 million for the three months ended June 30, 2016, compared to \$30.8 million for the comparable period in 2015. The decrease in revenue was primarily caused by the completion of certain large high margin customer projects in the comparable prior period.

System and wire revenue and aftermarket revenue as a percentage of total BEST Segment revenue were as follows (dollars in millions):

|                         | Three Months Ended June 30, |                               |                |                               |
|-------------------------|-----------------------------|-------------------------------|----------------|-------------------------------|
|                         | 2016                        |                               | 2015           |                               |
|                         | Revenue                     | Percentage of Segment Revenue | Revenue        | Percentage of Segment Revenue |
| System and wire revenue | \$ 27.7                     | 97.2%                         | \$ 29.8        | 96.8%                         |
| Aftermarket revenue     | 0.8                         | 2.8%                          | 1.0            | 3.2%                          |
| Total revenue           | <u>\$ 28.5</u>              | <u>100.0%</u>                 | <u>\$ 30.8</u> | <u>100.0%</u>                 |

System and wire revenue in the BEST Segment includes low and high temperature superconducting wire and superconducting devices, including magnets, linear accelerators and radio frequency cavities. Aftermarket revenues in the BEST Segment consist primarily of consumables sales.

### **Gross Profit and Operating Expenses**

For the three months ended June 30, 2016, gross profit margin in the BSI Segment increased to 47.7% from 44.4% for the comparable period in 2015. The increase is primarily caused by operating cost improvements resulting from recent restructuring and outsourcing actions, the impact of pricing increases within the Bruker BioSpin Group and the impact of a recent acquisition within the Bruker Nano Group, offset in part by weakness in certain Bruker Nano and Bruker CALID Group market segments and delays in European academic funding. BEST Segment gross margin decreased to 18.2% from 20.5% for the comparable period in 2015 due to revenue declines resulting from the completion of certain high margin orders in the prior comparable period.

In the three months ended June 30, 2016, selling, general and administrative expenses and research and development expenses in the BSI Segment increased to \$133.8 million, or 38.7% of segment revenue, from \$132.4 million, or 36.2% of segment revenue. Selling, general and administrative expenses and research and development expenses in the BEST Segment increased to \$3.9 million, or 13.7% of segment revenue, from \$3.6 million, or 11.7% of segment revenue, for the comparable period in 2015. The increase as a percentage of revenue in both segments is primarily caused by the decline in revenue during the three months ended June 30, 2016.

### **Operating Income**

The following table presents operating income and operating margins by reportable segment (dollars in millions):

|                                       | Three Months Ended June 30, |                               |                  |                               |
|---------------------------------------|-----------------------------|-------------------------------|------------------|-------------------------------|
|                                       | 2016                        |                               | 2015             |                               |
|                                       | Operating Income            | Percentage of Segment Revenue | Operating Income | Percentage of Segment Revenue |
| BSI                                   | \$ 18.9                     | 5.5%                          | \$ 28.7          | 7.8%                          |
| BEST                                  | 1.4                         | 4.9%                          | 2.6              | 8.4%                          |
| Corporate, eliminations and other (a) | 0.1                         |                               | 0.3              |                               |
| Total operating income                | \$ 20.4                     | 5.5%                          | \$ 31.6          | 8.0%                          |

(a) Represents corporate costs and eliminations not allocated to the reportable segments.

BSI Segment operating income for the three months ended June 30, 2016 was \$18.9 million, resulting in an operating margin of 5.5%, compared to operating income of \$28.7 million, resulting in an operating margin of 7.8%, for the comparable period in 2015. Operating income included \$19.5 million and \$11.0 million for the three months ended June 30, 2016 and 2015, respectively, of various charges for amortization of acquisition-related intangible assets and other acquisition-related costs, restructuring costs, and costs associated with our global IT transformation initiative. Excluding these charges, non-GAAP operating margins were 11.1% and 10.8% for the three months ended June 30, 2016 and 2015, respectively. Non-GAAP operating margins increased primarily due to the gross margin improvements noted above.

BEST Segment operating income for the three months ended June 30, 2016 was \$1.4 million, resulting in an operating margin of 4.9%, compared to \$2.6 million, resulting in an operating margin of 8.4%, for the comparable period in 2015. The decrease in operating margin was a result of lower gross margin levels as noted above.

*Six Months Ended June 30, 2016 compared to the Six Months Ended June 30, 2015*

### **Consolidated Results**

The following table presents our results for the six months ended June 30, 2016 and 2015 (dollars in millions, except per share data):

|                                                                                     | Six Months Ended June 30, |          |
|-------------------------------------------------------------------------------------|---------------------------|----------|
|                                                                                     | 2016                      | 2015     |
| Product revenue                                                                     | \$ 617.9                  | \$ 634.2 |
| Service revenue                                                                     | 124.2                     | 112.3    |
| Other revenue                                                                       | 5.0                       | 3.0      |
| Total revenue                                                                       | 747.1                     | 749.5    |
| Cost of product revenue                                                             | 332.5                     | 352.7    |
| Cost of service revenue                                                             | 75.4                      | 66.9     |
| Cost of other revenue                                                               | 2.3                       | 0.3      |
| Total cost of revenue                                                               | 410.2                     | 419.9    |
| Gross profit                                                                        | 336.9                     | 329.6    |
| Operating expenses:                                                                 |                           |          |
| Selling, general and administrative                                                 | 193.6                     | 193.1    |
| Research and development                                                            | 72.9                      | 74.7     |
| Other charges, net                                                                  | 16.0                      | 15.0     |
| Total operating expenses                                                            | 282.5                     | 282.8    |
| Operating income                                                                    | 54.4                      | 46.8     |
| Interest and other income (expense), net                                            | (8.2)                     | (9.7)    |
| Income before income taxes and noncontrolling interest in consolidated subsidiaries | 46.2                      | 37.1     |
| Income tax provision                                                                | 7.8                       | 7.1      |
| Consolidated net income                                                             | 38.4                      | 30.0     |
| Net income attributable to noncontrolling interest in consolidated subsidiaries     | 0.3                       | 1.6      |
| Net income attributable to Bruker Corporation                                       | \$ 38.1                   | \$ 28.4  |
| Net income per common share attributable to Bruker Corporation shareholders:        |                           |          |
| Basic and diluted                                                                   | \$ 0.23                   | \$ 0.17  |
| Weighted average common shares outstanding:                                         |                           |          |
| Basic                                                                               | 162.3                     | 168.3    |
| Diluted                                                                             | 163.3                     | 169.7    |

### Revenue

For the six months ended June 30, 2016, our revenue decreased \$2.4 million, or 0.3%, to \$747.1 million, compared to \$749.5 million for the comparable period in 2015. Included in revenue was a decrease of approximately \$3.1 million from the impact of foreign currency caused by the strengthening of the U.S. Dollar primarily versus the British Pound, as well as various other currencies, and an increase of approximately \$17.2 million attributable to a recent acquisition within the Bruker Nano Group. Excluding the effects of foreign currency and our recent acquisition, our organic revenue, a non-GAAP measure, decreased by \$16.5 million, or 2.2%.

BSI Segment revenue increased by \$2.4 million, or 0.3%, to \$696.1 million for the six months ended June 30, 2016, compared to \$693.7 million for the six months ended June 30, 2015. BEST Segment revenue decreased by \$2.6 million, or 4.5%, to \$55.7 million for the six months ended June 30, 2016, compared to \$58.3 million for the six months ended June 30, 2015.

Please see the Segment Results section later in this discussion for additional information regarding our revenue.

**Gross Profit**

Gross profit for the six months ended June 30, 2016 was \$336.9 million, or 45.1% of revenue, compared to \$329.6 million, or 44.0% of revenue, for the six months ended June 30, 2015. Included in gross profit were various charges for amortization of acquisition-related intangible assets and other acquisition-related costs and restructuring costs totaling \$15.4 million and \$15.9 million for the six months ended June 30, 2016 and 2015, respectively. Excluding these charges, our non-GAAP gross profit margin for the six months ended June 30, 2016 and 2015 was 47.2% and 46.1%, respectively. The increase in our gross profit margins was caused primarily by operating cost improvements as a result of recent restructuring and outsourcing actions, the impact of pricing increases within the Bruker BioSpin Group and the impact of a recent acquisition within the Bruker Nano Group. The favorable effect of these items was offset in part by weakness in Bruker Nano Group industrial market segments, delays in European academic funding within our Bruker CALID and Bruker Nano Groups, and a decline in the BEST Segment resulting from the completion of certain high margin orders in the comparable prior period.

**Selling, General and Administrative**

Our selling, general and administrative expenses for the six months ended June 30, 2016 increased to \$193.6 million, or 25.9% of total revenue, from \$193.1 million, or 25.8% of total revenue, for the comparable period in 2015. The increase in selling, general and administrative expenses was attributable to the impact of a recent acquisition within our Bruker Nano Group, which was partially offset by the impact of recent operational improvements as a result of our restructuring actions.

**Research and Development**

Our research and development expenses for the six months ended June 30, 2016 decreased to \$72.9 million, or 9.8% of total revenue, from \$74.7 million, or 10.0% of total revenue, for the comparable period in 2015. The decrease in research and development expenses was primarily attributable to the timing of certain research and development initiatives.

**Other Charges, Net**

Other charges, net of \$16.0 million recorded for the six months ended June 30, 2016 were all related to the BSI Segment and consisted mainly of \$7.9 million of acquisition-related charges, related primarily to additional contingent consideration recognized for a recent acquisition in the Bruker Nano Group based upon an increase in forecasted revenue levels of the acquired business for the remainder of 2016, \$3.6 million of restructuring costs related to closing facilities and implementing outsourcing and other restructuring initiatives and \$3.9 million of costs associated with our global IT transformation initiative.

Other charges, net of \$15.0 million recorded for the six months ended June 30, 2015 is almost entirely related to the BSI Segment. The charges consisted of a \$10.2 million one-time, non-cash settlement charge as the plan assets and pension obligations for the retirees and other certain members of the population within our pension plan in Switzerland were transferred to an outside insurance provider, (\$2.9) million of acquisition-related charges (benefits) primarily caused by the reversal of certain contingent consideration liabilities, \$1.8 million of long-lived asset impairments within the Magnetic Resonance division, \$2.3 million of restructuring costs related to closing facilities and implementing outsourcing and other restructuring initiatives and \$3.6 million of costs associated with our global IT transformation initiative.

**Operating Income**

Operating income for the six months ended June 30, 2016 was \$54.4 million, resulting in an operating margin of 7.3%, compared to operating income of \$46.8 million, resulting in an operating margin of 6.2%, for the six months ended June 30, 2015. The increase in operating margin was primarily caused by the gross margin improvements discussed above as well as operational improvements as a result of our restructuring initiatives.

The Company commenced a restructuring initiative in 2015 within the Bruker BioSpin Group, which was developed as a result of a revenue decline that occurred during the second half of 2014 and continued during the first half of 2015 and was intended to improve the Bruker BioSpin Group's operating results. Restructuring actions resulted in a reduction of employee headcount by approximately 9% and included the closure and consolidation of a Bruker BioSpin Group manufacturing facility. Income from operations included restructuring costs of \$3.3 million for the six months ended June 30, 2016 related to this initiative.

**Interest and Other Income (Expense), Net**

Interest and other income (expense), net during the six months ended June 30, 2016 was an expense of \$8.2 million compared to an expense of \$9.7 million for the comparable period of 2015.

During the six months ended June 30, 2016, the major components within interest and other income (expense), net were net interest expense of \$6.0 million and realized and unrealized losses on foreign currency denominated transactions of \$1.6 million. The realized and unrealized losses on foreign currency denominated transactions during the six months ended June 30, 2016 were primarily caused by the fluctuation of the U.S. dollar versus the Euro and other currencies. During the six months ended June 30, 2015, the components within interest and other income (expense), net were net interest expense of \$6.2 million and realized and unrealized losses on foreign currency denominated transactions of \$3.3 million.

### ***Income Tax Provision***

The 2016 and 2015 effective tax rates were estimated using projected annual pre-tax income or loss on a jurisdictional basis. Expected tax benefits, including tax credits and incentives, the impact of changes to valuation allowances, and the effect of jurisdictional differences in statutory tax rates, were also considered in the calculation.

The income tax provision for the six months ended June 30, 2016 and 2015 was \$7.8 million and \$7.1 million, respectively, representing effective tax rates of 16.9% and 19.1%, respectively. The decrease in our effective tax rate for the six months ended June 30, 2016, compared to the same period in 2015, was primarily caused by the recognition of previously unrecognized tax benefits due to the closure of certain tax audits and changes in the expected mix of earnings among tax jurisdictions.

### ***Net Income Attributable to Noncontrolling Interests***

Net income attributable to noncontrolling interests for the six months ended June 30, 2016 and 2015 was \$0.3 million and \$1.6 million, respectively. The net income attributable to noncontrolling interests represented the minority shareholders' proportionate share of the net income recorded by our majority-owned subsidiaries.

### ***Net Income Attributable to Bruker Corporation***

Our net income for the six months ended June 30, 2016 was \$38.1 million, or \$0.23 per diluted share, compared to \$28.4 million, or \$0.17 per diluted share, for the comparable period in 2015. The increase was primarily caused by increased gross profit, operating profit improvements, a lower effective tax rate and the impact of our share repurchase program.

### ***Segment Results***

For financial reporting purposes, we aggregate the Bruker BioSpin, Bruker CALID and Bruker Nano operating segments into the Bruker Scientific Instruments (BSI) reportable segment, which represented approximately 93% of the Company's revenues during the six months ended June 30, 2016. This aggregation reflects these operating segments' similar economic characteristics, production processes, service offerings, types and classes of customers, methods of distribution and regulatory environments. Our BEST Segment is our other reportable segment and represents the remainder of our revenues.

### ***Revenue***

The following table presents revenue, change in revenue and revenue growth by reportable segment (dollars in millions):

|                  | Six Months Ended June 30, |                 | Dollar Change   | Percentage Change |
|------------------|---------------------------|-----------------|-----------------|-------------------|
|                  | 2016                      | 2015            |                 |                   |
| BSI              | \$ 696.1                  | \$ 693.7        | \$ 2.4          | 0.3%              |
| BEST             | 55.7                      | 58.3            | (2.6)           | (4.5)%            |
| Eliminations (a) | (4.7)                     | (2.5)           | (2.2)           |                   |
|                  | <u>\$ 747.1</u>           | <u>\$ 749.5</u> | <u>\$ (2.4)</u> | <u>(0.3)%</u>     |

(a) Represents product and service revenue between reportable segments.

### ***BSI Segment Revenues***

BSI Segment revenue increased by \$2.4 million, or 0.3%, to \$696.1 million for the six months ended June 30, 2016, compared to \$693.7 million for the six months ended June 30, 2015. Included in revenue was a decrease of approximately

\$3.2 million from the impact of foreign currency caused by the strengthening of the U.S. Dollar primarily versus the British Pound, as well as other currencies, and an increase of approximately \$17.2 million attributable to a recent acquisition in our Bruker Nano Group. Excluding the effects of foreign currency and our recent acquisition, organic revenue, a non-GAAP measure, decreased by \$11.6 million, or 1.7%, with weaker sales in Europe and Japan driving the majority of the decrease.

The Bruker BioSpin Group revenues increased during the six months ended June 30, 2016 when compared to the six months ended June 30, 2015 due to increased sales associated with the fulfillment of significant prior year orders, increased pricing, and the recognition of revenues from the sale of the first shielded ultra-high field gigahertz nuclear magnetic resonance system and other ultra-high field systems.

The Bruker CALID Group revenues decreased during the six months ended June 30, 2016 when compared to the six months ended June 30, 2015 primarily due to delays in European academic funding and lower sales of our MALDI Biotyper in China and the U.S., partially offset by increases in sales of our Raman, near infrared and remote sensing products.

The Bruker Nano Group experienced a decrease in revenue, mainly caused by continued weaker demand within industrial markets and European academic funding delays during the six months ended June 30, 2016.

System revenue and aftermarket revenue as a percentage of total BSI Segment revenue were as follows (dollars in millions):

|                     | Six Months Ended June 30, |                               |          |                               |
|---------------------|---------------------------|-------------------------------|----------|-------------------------------|
|                     | 2016                      |                               | 2015     |                               |
|                     | Revenue                   | Percentage of Segment Revenue | Revenue  | Percentage of Segment Revenue |
| System revenue      | \$ 501.5                  | 72.0%                         | \$ 510.2 | 73.5%                         |
| Aftermarket revenue | 194.6                     | 28.0%                         | 183.5    | 26.5%                         |
| Total revenue       | \$ 696.1                  | 100.0%                        | \$ 693.7 | 100.0%                        |

System revenue in the BSI Segment includes nuclear magnetic resonance systems, magnetic resonance imaging systems, electron paramagnetic imaging systems, mass spectrometry systems, gas chromatography systems, CBRNE detection systems, X-ray systems, spark-optical emission spectroscopy systems, atomic force microscopy systems, stylus and optical metrology systems and molecular spectroscopy systems. Aftermarket revenues in the BSI Segment include accessory sales, consumables, training and services.

#### **BEST Segment Revenues**

BEST Segment revenue decreased \$2.6 million, or 4.5%, to \$55.7 million for the six months ended June 30, 2016, compared to \$58.3 million for the comparable period in 2015. The decrease in revenue was primarily caused by the completion of certain large high margin customer projects in the comparable prior period.

System and wire revenue and aftermarket revenue as a percentage of total BEST Segment revenue were as follows (dollars in millions):

|                         | Six Months Ended June 30, |                               |         |                               |
|-------------------------|---------------------------|-------------------------------|---------|-------------------------------|
|                         | 2016                      |                               | 2015    |                               |
|                         | Revenue                   | Percentage of Segment Revenue | Revenue | Percentage of Segment Revenue |
| System and wire revenue | \$ 54.1                   | 97.1%                         | \$ 56.1 | 96.2%                         |
| Aftermarket revenue     | 1.6                       | 2.9%                          | 2.2     | 3.8%                          |
| Total revenue           | \$ 55.7                   | 100.0%                        | \$ 58.3 | 100.0%                        |

System and wire revenue in the BEST Segment includes low and high temperature superconducting wire and superconducting devices, including magnets, linear accelerators and radio frequency cavities. Aftermarket revenues in the BEST Segment consist primarily of consumables sales.

### Gross Profit and Operating Expenses

For the six months ended June 30, 2016, gross profit margin in the BSI Segment increased to 47.0% from 45.8% for the comparable period in 2015. The increase in gross margin percentage was caused primarily by operating cost improvements resulting from recent restructuring and outsourcing actions, the impact of pricing increases within the Bruker BioSpin Group and the impact of a recent acquisition within the Bruker Nano Group, offset by weakness in certain Bruker Nano and Bruker CALID Group market segments and delays in European academic funding. BEST Segment gross margin decreased to 16.0% from 19.4% for the comparable period in 2015 caused by the completion of certain high margin orders in the comparable prior period.

In the six months ended June 30, 2016, selling, general and administrative expenses and research and development expenses in the BSI Segment decreased to \$258.9 million, or 37.2% of segment revenue, from \$260.3 million, or 37.5% of segment revenue. The decrease reflected the favorable impact of changes in foreign currency and recent operational improvement and restructuring actions. Selling, general and administrative expenses and research and development expenses in the BEST Segment increased to \$7.6 million, or 13.6% of segment revenue, from \$7.5 million, or 12.9% of segment revenue, for the comparable period in 2015. The increase as a percentage of revenue was primarily caused by the lower revenue levels for the six months ended June 30, 2016 as compared to the prior period.

### Operating Income

The following table presents operating income and operating margins by reportable segment (dollars in millions):

|                                       | Six Months Ended June 30, |                                     |                     |                                     |
|---------------------------------------|---------------------------|-------------------------------------|---------------------|-------------------------------------|
|                                       | 2016                      |                                     | 2015                |                                     |
|                                       | Operating<br>Income       | Percentage of<br>Segment<br>Revenue | Operating<br>Income | Percentage of<br>Segment<br>Revenue |
| BSI                                   | \$ 51.9                   | 7.5%                                | \$ 42.4             | 6.1%                                |
| BEST                                  | 1.4                       | 2.5%                                | 3.6                 | 6.2%                                |
| Corporate, eliminations and other (a) | 1.1                       |                                     | 0.8                 |                                     |
| Total operating income                | \$ 54.4                   | 7.3%                                | \$ 46.8             | 6.2%                                |

(a) Represents corporate costs and eliminations not allocated to the reportable segments.

BSI Segment operating income for the six months ended June 30, 2016 was \$51.9 million, resulting in an operating margin of 7.5%, compared to operating income of \$42.4 million, resulting in an operating margin of 6.1%, for the comparable period in 2015. Operating income included \$32.8 million and \$31.6 million for the six months ended June 30, 2016 and 2015, respectively, of various charges for amortization of acquisition-related intangible assets and other acquisition-related costs, restructuring costs, and costs associated with our global IT transformation initiative. Excluding these charges, non-GAAP operating margins were 12.2% and 10.7% for the six months ended June 30, 2016 and 2015, respectively. Our operating margins increased primarily due to the gross margin improvements noted above.

BEST Segment operating income for the six months ended June 30, 2016 was \$1.4 million, resulting in an operating margin of 2.5%, compared to \$3.6 million, resulting in an operating margin of 6.2%, for the comparable period in 2015. The decrease in operating margin was caused by the lower gross margin levels as noted above.

### LIQUIDITY AND CAPITAL RESOURCES

We anticipate that our existing cash and credit facilities will be sufficient to support our operating and investing needs for at least the next twelve months. Our future cash requirements could be affected by acquisitions that we may make in the future, dividend payments, share repurchases or changes in our capital structure. Historically, we have financed our growth through cash flow generation and a combination of debt financings and issuances of common stock. In the future, there are no

assurances that additional financing alternatives will be available to us if required, or, if available, will be obtained on terms favorable to us.

During the six months ended June 30, 2016, net cash used in operating activities was \$4.1 million, resulting from consolidated net income adjusted for non-cash items of \$82.9 million, offset by an increase in operating assets and liabilities, net of acquisitions and divestitures of \$78.8 million. The increase in operating assets and liabilities, net of acquisitions and divestitures for the six months ended June 30, 2016 was primarily caused by an increase in inventory needed to fulfill orders in the second half of 2016, the timing of customer advances received and installation and acceptance of the systems, and tax payments, including withholding tax payments made in the first quarter of 2016 related to the Company's 2015 European cash repatriation. These uses of cash were partially offset by a decrease in accounts receivable resulting from lower revenue levels, higher than normal collection of receivables in the fourth quarter of 2015 and improvements in collections and customer credit management practices.

During the six months ended June 30, 2015, net cash provided by operating activities was \$25.5 million, resulting from consolidated net income adjusted for non-cash items of \$70.7 million, partially offset by an increase in operating assets and liabilities, net of acquisitions and divestitures of \$45.2 million. The increase in operating assets and liabilities, net of acquisitions and divestitures for the six months ended June 30, 2015 was primarily caused by an increase in inventory needed to fulfill orders in the second half of 2015, income tax payments made during the first half of the year, and an increase in non-income tax receivables. These uses of cash were partially offset by a decrease in accounts receivable. The decrease in accounts receivable was predominantly the result of lower revenue levels and improvements in collections and customer credit management practices.

During the six months ended June 30, 2016, net cash used in investing activities was \$0.5 million, compared to net cash used in investing activities of \$21.5 million during the six months ended June 30, 2015. Cash used in investing activities during the six months ended June 30, 2016 was primarily caused by purchases of property, plant and equipment, net of proceeds from the sale of property, plant and equipment, of \$16.3 million offset by net maturities in short-term investments of \$17.0 million. Cash used in investing activities during the six months ended June 30, 2015 was caused by capital expenditures, net of \$12.7 million and net purchases of short-term investments of \$8.8 million.

During the six months ended June 30, 2016, net cash used in financing activities was \$42.8 million, compared to net cash provided by financing activities of \$1.1 million during the six months ended June 30, 2015. Net cash used in financing activities during the six months ended June 30, 2016 was primarily attributable to \$117.6 million used for the repurchase of our common stock and \$13.0 million used for the payment of dividends. This was offset by \$77.0 million of proceeds from borrowings under the 2015 Credit Agreement, as defined below, and \$9.6 million of proceeds from the issuance of common stock in connection with stock option exercises. Net cash provided by financing activities during the six months ended June 30, 2015 was primarily attributable to \$17.2 million used for the repurchase of our common stock offset by \$10.0 million of proceeds from borrowings under our revolving line of credit and \$6.2 million of proceeds from the issuance of common stock in connection with stock option exercises.

In November 2015, our Board of Directors suspended the previously announced Anti-Dilutive Repurchase Program until January 1, 2017 and approved an additional share repurchase program (the "Repurchase Program") under which repurchases of common stock up to \$225.0 million may occur from time to time, in amounts, at prices, and at such times as we deem appropriate, subject to market conditions, legal requirements and other considerations. A total of 4,577,858 shares were repurchased at an aggregate cost of \$117.6 million in the six months ended June 30, 2016 and 7,414,900 shares were repurchased at an aggregate cost of \$182.6 million from the inception of the Repurchase Program through June 30, 2016. Any future repurchases will be funded by cash on hand, future cash flows from operations and available borrowings under the revolving credit facility.

Cash, cash equivalents and short-term investments at June 30, 2016 and December 31, 2015 totaled \$420.4 million and \$468.3 million, respectively, of which \$389.1 million and \$420.9 million, respectively, related to foreign cash and short-term investments, most significantly in the Netherlands and Switzerland.

We assert that our foreign earnings, with the exception of our foreign earnings that have been previously taxed by the U.S., are indefinitely reinvested. We regularly evaluate our assertion that our foreign earnings are indefinitely reinvested. If the cash, cash equivalents and short-term investments held by our foreign subsidiaries are needed to fund operations in the U.S., or we otherwise elect to repatriate the unremitted earnings of our foreign subsidiaries in the form of dividends or otherwise, or if the shares of the subsidiaries were sold or transferred, we would likely be subject to additional U.S. income taxes, net of the impact of any available tax credits, which could result in a higher effective tax rate in the future.

At June 30, 2016, we had outstanding debt totaling \$343.0 million, consisting of \$240.0 million outstanding under the Note Purchase Agreement described below, \$102.0 million outstanding under the revolving credit line component of the 2015 Credit Agreement described below and \$1.9 million under capital lease obligations and other loans, offset by unamortized debt issuance costs under the Note Purchase Agreement of \$0.9 million. At December 31, 2015, we had outstanding debt totaling \$265.8 million, consisting of \$240.0 million outstanding under the Note Purchase Agreement, \$25.0 million outstanding under the revolving credit line component of the prior credit agreement and \$1.7 million under capital lease obligations and other loans, offset by unamortized debt issuance costs under the Note Purchase Agreement of \$0.9 million.

The following is a summary of the maximum commitments and the net amounts available to us under the 2015 Credit Agreement and other lines of credit with various financial institutions located primarily in Germany and Switzerland that are unsecured and typically due upon demand with interest payable monthly, at June 30, 2016 (in millions):

|                                 | Weighted<br>Average<br>Interest Rate | Total Amount<br>Committed by<br>Lenders | Outstanding<br>Borrowings | Outstanding<br>Lines of Credit | Total Amount<br>Available |
|---------------------------------|--------------------------------------|-----------------------------------------|---------------------------|--------------------------------|---------------------------|
| 2015 Credit Agreement           | 1.6%                                 | \$ 500.0                                | \$ 102.0                  | \$ 1.1                         | \$ 396.9                  |
| Other lines of credit           | —                                    | 238.0                                   | —                         | 129.2                          | 108.8                     |
| Total revolving lines of credit |                                      | \$ 738.0                                | \$ 102.0                  | \$ 130.3                       | \$ 505.7                  |

On October 27, 2015, we entered into a revolving credit agreement, referred to as the 2015 Credit Agreement, and terminated the prior credit agreement. The 2015 Credit Agreement provides a maximum commitment on the revolving credit line of \$500.0 million and a maturity date of October 2020. Borrowings under the revolving credit line of the 2015 Credit Agreement accrue interest, at the Company's option, at either (a) the greatest of (i) the prime rate, (ii) the federal funds rate plus 0.50% and (iii) adjusted LIBOR plus 1.00%, plus margins ranging from 0.00% to 0.30% or (b) LIBOR, plus margins ranging from 0.90% to 1.30%. There is also a facility fee ranging from 0.10% to 0.20%.

Borrowings under the 2015 Credit Agreement are secured by guarantees from certain material subsidiaries, as defined in the 2015 Credit Agreement. The 2015 Credit Agreement also requires us to maintain certain financial ratios related to maximum leverage and minimum interest coverage. Specifically, our leverage ratio cannot exceed 3.5 and our interest coverage ratio cannot be less than 2.5. In addition to the financial ratios, the 2015 Credit Agreement contains negative covenants, including among others, restrictions on liens, indebtedness of the Company and its subsidiaries, asset sales, dividends and transactions with affiliates. Failure to comply with any of these restrictions or covenants may result in an event of default on the 2015 Credit Agreement, which could permit acceleration of the debt and require us to prepay the debt before its scheduled due date.

In January 2012, we entered into a note purchase agreement, referred to as the Note Purchase Agreement, with a group of accredited institutional investors. Pursuant to the Note Purchase Agreement, we issued and sold \$240.0 million of senior notes, referred to as the Senior Notes, which consist of the following:

- \$20.0 million 3.16% Series 2012A Senior Notes, Tranche A, due January 18, 2017;
- \$15.0 million 3.74% Series 2012A Senior Notes, Tranche B, due January 18, 2019;
- \$105.0 million 4.31% Series 2012A Senior Notes, Tranche C, due January 18, 2022; and
- \$100.0 million 4.46% Series 2012A Senior Notes, Tranche D, due January 18, 2024.

As of June 30, 2016, we were in compliance with the covenants, as defined by both the 2015 Credit Agreement and the Note Purchase Agreement, as our leverage ratio was 1.3 and our interest coverage ratio was 15.2.

As of June 30, 2016, we had approximately \$3.0 million of net operating loss carryforwards available to reduce state taxable income; approximately \$43.1 million of net operating losses available to reduce German federal income and trade taxes that are carried forward indefinitely; and \$47.0 million of other foreign net operating losses that are expected to expire at various times beginning in 2018. We also had U.S. federal tax credits of approximately \$27.8 million that expire at various dates available to offset future tax liabilities, which include research and development tax credits of \$14.0 million expiring at

various times through 2035, foreign tax credits of \$13.8 million expiring at various times through 2024, and state research and development tax credits of \$7.1 million. Utilization of these credits and state net operating losses may be subject to annual limitations due to the ownership percentage change limitations provided by the Internal Revenue Code Section 382 and similar state provisions. In the event of a deemed change in control under Internal Revenue Code Section 382, an annual limitation on the utilization of net operating losses and credits may result in the expiration of all or a portion of the net operating loss and credit carryforwards.

## RECENT ACCOUNTING PRONOUNCEMENTS

In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-09, *Stock Compensation - Improvements to Employee Share-Based Payment Accounting*. The new standard simplifies accounting for share-based payment transactions, including income tax consequences and the classification of the tax impact on the statement of cash flows. The new standard is effective as of January 1, 2017, and early adoption is permitted. We are evaluating the provisions of this statement, including which period to adopt, and have not determined what impact the adoption of ASU No. 2016-09 will have on our unaudited condensed consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, *Leases*. The new standard provides guidance on the recognition, measurement, presentation, and disclosure of leases. The new standard supersedes present U.S. GAAP guidance on leases and requires substantially all leases to be reported on the balance sheet as right-of-use assets and lease liabilities, as well as additional disclosures. The new standard is effective as of January 1, 2019, and early adoption is permitted. We are evaluating the provisions of this statement, including which period to adopt, and have not determined what impact the adoption of ASU No. 2016-02 will have on our unaudited condensed consolidated financial statements.

In July 2015, the FASB issued Accounting Standards Update ASU No. 2015-11, *Simplifying the Measurement of Inventory*. The new guidance eliminates the measurement of inventory at market value, and inventory will now be measured at the lower of cost and net realizable value. The ASU defines net realizable value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. No other changes were made to the current guidance on inventory measurement. ASU No. 2015-11 is effective for interim and annual periods beginning after December 15, 2016. Early application is permitted and should be applied prospectively. We are evaluating the provisions of this statement, including which period to adopt, and have not determined what impact the adoption of ASU No. 2015-11 will have on our unaudited condensed consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, *Revenue from Contracts with Customers*, which supersedes the revenue recognition requirements under Accounting Standards Codification (ASC) Topic 605. The new guidance was the result of a joint project between the FASB and the International Accounting Standards Board to clarify the principles for recognizing revenue and to develop common revenue standards for GAAP and International Financial Reporting Standards. The core principle of the new guidance is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB elected to defer the effective date of ASU No. 2014-09 by one year to annual periods beginning after December 15, 2017, with early application permitted as of the previous effective date of December 15, 2016. We are currently assessing the impact adoption of the new guidance may have on our unaudited condensed consolidated financial statements.

## ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are potentially exposed to market risks associated with changes in foreign currency, interest rates and commodity prices. We selectively use financial instruments to reduce these risks. All transactions related to risk management techniques are authorized and executed pursuant to our policies and procedures. Analytical techniques used to manage and monitor foreign currency and interest rate risk include market valuations and sensitivity analysis.

### *Impact of Foreign Currencies*

We generate a substantial portion of our revenues in international markets, principally Germany and other countries in the European Union, Switzerland and Japan, which exposes our operations to the risk of exchange rate fluctuations. The impact of currency exchange rate movement can be positive or negative in any period. Our costs related to sales in foreign currencies are largely denominated in the same respective currencies, reducing our transaction risk exposure. However, for foreign currency

denominated sales in certain regions, such as Japan, where we do not incur significant costs denominated in that foreign currency, we are more exposed to the impact of foreign currency fluctuations.

For sales not denominated in U.S. Dollars, if there is an increase in the rate at which a foreign currency is exchanged for U.S. Dollars, it will require more of the foreign currency to equal a specified amount of U.S. Dollars than before the rate increase. In such cases, if we price our products in the foreign currency, we will receive less in U.S. Dollars than we would have received before the rate increase went into effect. If we price our products in U.S. Dollars and competitors price their products in local currency, an increase in the relative strength of the U.S. Dollar could result in our prices not being competitive in a market where business is transacted in the local currency. For example, if the U.S. Dollar further strengthened against the Japanese Yen, our Japanese-based competitors would have a greater pricing advantage over us.

Changes in foreign currency translation rates decreased our revenue by 0.4% for the six months ended June 30, 2016 and decreased our revenue by approximately 11.3% for the six months ended June 30, 2015.

Assets and liabilities of our foreign subsidiaries, where the functional currency is the local currency, are translated into U.S. dollars using period-end exchange rates. Revenues and expenses of foreign subsidiaries are translated at the average exchange rates in effect during the year. Adjustments resulting from financial statement translations are included as a separate component of shareholders' equity. For the six months ended June 30, 2016 and 2015, we recorded net gains (losses) from currency translation adjustments of \$15.0 million and \$(37.1) million, respectively. Gains and losses resulting from foreign currency transactions are reported in interest and other income (expense), net in the unaudited condensed consolidated statements of income and comprehensive income. Our foreign exchange losses, net were \$1.6 million and \$3.3 million for the six months ended June 30, 2016 and 2015, respectively.

From time to time, we have entered into foreign exchange contracts designed to minimize the volatility that fluctuations in foreign currency have on our cash flows related to purchases and sales denominated in foreign currencies. Under these arrangements, we agree to purchase a fixed amount of a foreign currency in exchange for a fixed amount of U.S. Dollars or other currencies on specified dates typically with maturities of less than twelve months. These transactions are recorded at fair value with the corresponding gains and losses recorded in interest and other income (expense), net in the unaudited condensed consolidated statements of income and comprehensive income. At June 30, 2016 and December 31, 2015, we had foreign exchange contracts with notional amounts aggregating \$46.1 million and \$36.2 million, respectively. We will continue to evaluate our currency risks and in the future may utilize foreign currency contracts more frequently.

#### ***Impact of Interest Rates***

We regularly invest excess cash in short-term investments that are subject to changes in interest rates. We believe that the market risk arising from holding these financial instruments is minimal because of our policy of investing in short-term financial instruments issued by highly rated financial institutions.

Our exposure related to adverse movements in interest rates is derived primarily from outstanding floating rate debt instruments that are indexed to short-term market rates. We currently have a higher level of fixed rate debt, which limits our exposure to adverse movements in interest rates.

#### ***Impact of Commodity Prices***

We are exposed to certain commodity risks associated with prices for various raw materials. The prices of copper and certain other raw materials, particularly niobium tin, used to manufacture superconductors have increased significantly over the last decade. Copper and niobium tin are the main components of low temperature superconductors and continued commodity price increases for copper and niobium as well as other raw materials may negatively affect our profitability. Periodically, we enter into commodity forward purchase contracts to minimize the volatility that fluctuations in the price of copper have on our sales of these products. At June 30, 2016 and December 31, 2015, we had fixed price commodity contracts with notional amounts aggregating \$0.9 million and \$2.0 million, respectively. We will continue to evaluate our commodity risks and may utilize commodity forward purchase contracts more frequently in the future.

#### ***Inflation***

We do not believe inflation had a material impact on our business or operating results during any of the periods presented.

**ITEM 4. CONTROLS AND PROCEDURES**

We have established disclosure controls and procedures that are designed to ensure that material information relating to us, including our consolidated subsidiaries, is made known to our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer) by others within our organization. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of June 30, 2016. Based on this evaluation our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2016 to ensure that the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms.

There were no changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2016 that materially affected, or are reasonably likely to affect, our internal control over financial reporting.

**PART II OTHER INFORMATION****ITEM 1. LEGAL PROCEEDINGS**

The Company understands that the Korea Fair Trade Commission ("KFTC") is conducting an investigation into improper bidding by Bruker Korea Co., Ltd. and several other companies in connection with bids for sales of X-ray systems in 2010 and 2012. Three of the bids under investigation involved Bruker Korea. We are cooperating fully with the KFTC regarding this matter. The potential range of penalties which may arise as a result of any proceedings which may be brought by the KFTC or other Korean government agencies against the Company or its subsidiaries operating in Korea involving this matter could include the imposition of a civil and/or criminal fine and a suspension of all or a portion of the Company's operations from bidding for or conducting sales to Korean governmental agencies for a period of time. At this time we cannot reasonably assess the timing or outcome of these matters or their effect, if any, on our business or results of operations. Sales to customers in Korea were approximately 2% of our revenue for the year ended December 31, 2015.

**ITEM 1A. RISK FACTORS**

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2015, which could materially affect our business, financial condition or future results. The risks described in this report and in our Annual Report on Form 10-K are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

The following table sets forth all purchases made by or on behalf of the Company or any "affiliated purchaser," as defined in Rule 10b-18(a)(3) under the Exchange Act, of shares of our common stock during each month in the second quarter of 2016.

| Period                   | Total Number of Shares Purchased (1) | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2) | Maximum Number of Shares (or approximate dollar value) that May Yet Be Purchased Under the Plans or Programs (3) |
|--------------------------|--------------------------------------|------------------------------|--------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| April 1 - April 30, 2016 | 1,050,000                            | \$ 28.85                     | 1,050,000                                                                            | \$ 46,554,257                                                                                                    |
| May 1 - May 31, 2016     | 152,170                              | 28.07                        | 150,000                                                                              | 42,341,627                                                                                                       |
| June 1 - June 30, 2016   | 4,174                                | 23.95                        | —                                                                                    | 42,341,627                                                                                                       |
|                          | <u>1,206,344</u>                     | <u>\$ 28.74</u>              | <u>1,200,000</u>                                                                     |                                                                                                                  |

- (1) Includes (i) shares repurchased under a \$225.0 million share repurchase program approved by the Board of Directors and announced on November 13, 2015 (the “Repurchase Program”), under which repurchases of common stock may occur from time to time, in amounts, at prices, and at such times as the Company deems appropriate, subject to market conditions, legal requirements and other considerations, (ii) 2,170 shares surrendered by participants under our long-term incentive plans to pay taxes upon vesting of restricted stock awards, and (iii) 4,174 shares purchased by Frank H. Laukien, the Company’s Chief Executive Officer and Chairman of the Board of Directors, which was previously disclosed on a Form 4 filed with the SEC on June 15, 2016.
- (2) Represents shares repurchased under the Repurchase Program.
- (3) The Repurchase Program authorizes purchases of up to \$225.0 million of the Company’s common stock over a two-year period commencing November 12, 2015. As of June 30, 2016, approximately \$182.6 million of common shares have been repurchased. The Repurchase Program expires November 11, 2017 and can be suspended, modified or terminated at any time without prior notice. The Company had previously announced on May 20, 2015 a program approved by the Board of Directors (the “Anti-Dilutive Repurchase Program”) under which repurchases were authorized in an amount intended to approximately offset, on an annual basis, the dilutive effect of shares that are or may be issued pursuant to stock option and restricted stock awards under our long-term incentive plans. The Anti-Dilutive Repurchase Program was suspended until January 1, 2017 upon the approval of the Repurchase Program.

**ITEM 3.        DEFAULTS UPON SENIOR SECURITIES**

None.

**ITEM 4.        MINE SAFETY DISCLOSURE**

Not applicable.

**ITEM 5.        OTHER INFORMATION**

None.

**ITEM 6.        EXHIBITS**

| <b>Exhibit No.</b> | <b>Description</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.1               | Bruker Corporation 2016 Incentive Compensation Plan Form of Incentive Stock Option Award Agreement(1)                                                                                                                                                                                                                                                                                                                                                                                           |
| 10.2               | Bruker Corporation 2016 Incentive Compensation Plan Form of Non-Qualified Stock Option Award Agreement(1)                                                                                                                                                                                                                                                                                                                                                                                       |
| 10.3               | Bruker Corporation 2016 Incentive Compensation Plan Form of Restricted Stock Unit Award Agreement(1)                                                                                                                                                                                                                                                                                                                                                                                            |
| 31.1               | Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002(1)                                                                                                                                                                                                                                                                                                                                                                                           |
| 31.2               | Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002(1)                                                                                                                                                                                                                                                                                                                                                                                           |
| 32.1               | Certification by Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002(2)                                                                                                                                                                                                                                                                                                                |
| 101                | The following materials from the Bruker Corporation Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2016 formatted in Extensible Business Reporting Language (XBRL): (i) the Unaudited Condensed Consolidated Statements of Income and Comprehensive Income, (ii) the Unaudited Condensed Consolidated Balance Sheets, (iii) the Unaudited Condensed Consolidated Statements of Cash Flows and (iv) Notes to the Unaudited Condensed Consolidated Financial Statements(1) |

(1) Filed herewith.

(2) Furnished herewith.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

### BRUKER CORPORATION

Date: August 5, 2016

By: /s/ FRANK H. LAUKIEN, PH.D.  
Frank H. Laukien, Ph.D.  
*President, Chief Executive Officer and Chairman*  
*(Principal Executive Officer)*

Date: August 5, 2016

By: /s/ ANTHONY L. MATTACCHIONE  
Anthony L. Mattacchione  
*Chief Financial Officer and Senior Vice President*  
*(Principal Financial Officer)*

BRUKER CORPORATION  
FORM OF STOCK OPTION AGREEMENT  
UNDER 2016 INCENTIVE COMPENSATION PLAN

INCENTIVE STOCK OPTION

AGREEMENT entered into [ ] by and between Bruker Corporation, a Delaware corporation with a principal place of business in Billerica, Massachusetts (the “Company”), and the undersigned employee (the “Employee”) of the Company or one of its subsidiaries (the Company and its subsidiaries herein together referred to as the “Company”).

1. The Company desires to grant the Employee an incentive stock option under the Company’s 2016 Incentive Compensation Plan (the “2016 Plan”) to acquire shares of the Company’s common stock, \$.01 par value per share (the “Shares”).

2. Section 6 of the 2016 Plan provides that each option is to be evidenced by an award agreement, setting forth the terms and conditions of the option.

ACCORDINGLY, in consideration of the premises and of the mutual covenants and agreements contained herein, the Company and the Employee hereby agree as follows:

1. Grant of Option. The Company hereby grants under the 2016 Plan and subject to the terms and conditions of the 2016 Plan to the Employee an incentive stock option (the “Option”) to purchase all or any part of an aggregate of [ ] Shares on the terms and conditions hereinafter set forth.

2. Purchase Price. The purchase price (“Purchase Price”) for the Shares covered by the Option shall be \$[ ] per Share.

3. Time of Exercise of Option.

(a) The Option shall not be exercisable prior to one (1) year from grant. Thereafter, the Option shall be exercisable as follows:

| <u>On or After</u> | <u>Percentage of<br/>Shares Becoming<br/>Available for<br/>Exercise</u> | <u>Cumulative<br/>Percentage<br/>Available</u> |
|--------------------|-------------------------------------------------------------------------|------------------------------------------------|
| 12 months          | 25%                                                                     | 25%                                            |
| 24 months          | 25%                                                                     | 50%                                            |
| 36 months          | 25%                                                                     | 75%                                            |
| 48 months          | 25%                                                                     | 100%                                           |

Exciseability of the Option upon a Change in Control shall be determined as provided in Section 13 of the 2016 Plan.

4. Term of Options; Exercisability

(a) Each Option shall expire not more than ten (10) years from the date of the granting thereof, but shall be subject to earlier termination as herein provided.

(b) Except as otherwise provided in this Section 4, if the Employee ceases to be an employee of the Company, the Option granted to the Employee hereunder shall terminate on the date that is ninety (90) days after the Employee ceases to be an employee of the Company, or on the date on which the Option expires by its terms, whichever occurs first, and the Option shall not be exercisable after such date.

(c) If such termination of employment is because the Employee has become permanently disabled (within the meaning of Section 22(e) (3) of the Internal Revenue Code of 1986, as amended (the "Code")), such Option shall terminate ninety (90) days from the date the Employee ceases to be an employee, or on the date on which the Option expires by its terms, whichever occurs first.

(d) If such termination of employment is "for cause", all outstanding and unexercised portions of the Option as of the time the Employee is notified that the Employee's employment is terminated "for cause" will immediately be forfeited. For purposes of this Agreement, "cause" shall include (and is not limited to) dishonesty with respect to the Company or any of its affiliates, breach of fiduciary duty, insubordination, substantial malfeasance or non-feasance of duty, unauthorized disclosure of confidential information, material failure or refusal to comply with Company's published policies generally applicable to all employees, and conduct materially harmful to the business of the Company or any of its affiliates. The determination of the Compensation Committee (as defined in the 2016 Plan) as to the existence of "cause" will be conclusive on the Employee and the Company. In addition, "cause" is not limited to events which have occurred prior to the Employee's termination of employment, nor is it necessary that the Compensation Committee's finding of "cause" occur prior to termination. If the Compensation Committee determines, subsequent to the Employee's termination of employment but prior to the exercise of the Option, or any portion thereof, that either prior or subsequent to the Employee's termination the Employee engaged in conduct which would constitute "cause", then the right to exercise any outstanding unexercised portion of the Option will be immediately forfeited. Notwithstanding the foregoing, any definition in an agreement between the Employee and the Company which (i) contains a conflicting definition of "cause" for termination and (ii) is in effect at the time of such termination shall supersede the definition in this Agreement with respect to the Employee.

(e) In the event of the death of the Employee, the Option granted to the Employee shall terminate ninety (90) days from the date of death, or on the date on which the Option expires by its terms, whichever occurs first.

(f) If the Employees cease to be an employee of the Company, the Option shall be exercisable only to the extent that the right to purchase Shares under such Option, as provided in Section 3, has accrued and is in effect on the date of termination of employment.

(g) No partial exercise may be made for less than one (1) full Share.

(h) In the event of the death of the Employee, the Option may be exercised by the estate of the Employee, or by any person or persons who acquired the right to exercise the Option by will or pursuant to the laws of descent and distribution as a result of the death of the Employee, subject to Section 4(d) hereof.

5. Manner of Exercise of Option .

(a) To the extent that the right to exercise the Option has accrued and is in effect, the Option may be exercised in full or in part by giving written notice to the Company stating the number of Shares exercised and accompanied by payment in full for such Shares. Payment shall be made (a) in cash or by check payable to the order of the Company, (b) at the discretion of the Compensation Committee, and so long as there is no adverse tax or accounting impact to the Company, by delivery of Shares owned by the Employee having a fair market value equal in amount to the exercise price of the Option being exercised and having been held by the Employee for at least six months, (c) at the discretion of the Compensation Committee, by delivery of a properly executed exercise notice to the Company, together with a copy of irrevocable instructions to a broker to deliver promptly to the Company the amount of sale or loan proceeds to pay the exercise price, (d) at the discretion of the Compensation Committee, by a “net exercise” arrangement pursuant to which the Company will reduce the number of Shares issued upon exercise by the largest whole number of Shares with a fair market value that does not exceed the aggregate exercise price, together with cash or other payment from the Employee to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole Shares, or (e) at the discretion of the Compensation Committee, by any combination of (a), (b), (c) and (d) above. Upon such exercise, delivery of a certificate for paid-up, non-assessable Shares shall be made at the principal office of the Company to the person exercising the Option, not more than thirty (30) days from the date of receipt of the notice by the Company.

(b) The Company shall at all times during the term of the Option reserve and keep available such number of Shares of its common stock as will be sufficient to satisfy the requirements of the Option. The Employee shall not have any of the rights of a stockholder of the Company in respect of the Shares until one or more certificates for such Shares shall be delivered to him or her upon the due exercise of the Option.

6. Non-Transferability . The right of the Employee to exercise the Option shall not be assignable or transferable by the Employee otherwise than by will or the laws of descent and distribution, and the Option may be exercised during the lifetime of the Employee only by him or her. The Option shall be null and void and without effect upon the bankruptcy of the Employee or upon any attempted assignment or transfer, except as hereinabove provided, including without limitation any purported assignment, whether voluntary or by operation of law, pledge, hypothecation or other disposition contrary to the provisions hereof, or levy of execution, attachment, divorce, trustee process or similar process, whether legal or equitable, upon the Option.

7. Registration; Compliance with Laws and Regulations; Restrictive Legends .

(a) This Option and the obligation of the Company to sell and deliver Shares hereunder shall be subject in all respects to: (i) all applicable Federal and state laws, rules and regulations; and (ii) any registration, qualification, approvals or other requirements imposed by any government or regulatory agency or body which the Company shall, in its discretion, determine to be necessary or applicable. Moreover, the Option may not be exercised if its exercise, or the receipt of Shares pursuant thereto, would be contrary to applicable law. The Company intends, but is not obligated, to register the Shares for issuance under the Securities Act of 1933, as amended (the “Act”), and to keep such registration effective throughout the period the Option is exercisable.

(b) In the event that for any reason the Shares to be issued upon exercise of the Option shall not be effectively registered under the Act, upon any date on which the Option is exercised in whole or in part, the Employee (or the person permitted to exercise the Option in the event of Employee’s death or incapacity) shall execute and deliver to the Company, prior to the delivery of any Shares by the Company pursuant to this Agreement, an agreement (in such form as the Company may specify) in which the Employee (or such person) represents and warrants that such Shares are being

acquired for the Employee's own account, for investment only and not with a view to public resale or distribution, and represents and agrees that any subsequent offer for sale or distribution of any kind of such Shares shall be made only pursuant to either (i) a registration statement on an appropriate form under the Act, which registration statement has become effective and is current with regard to the Shares being offered or sold; or (ii) a specific exemption from the registration requirements of the Securities Act. Additionally, the Employee (or the person permitted to exercise the Option in the event of Employee's death or incapacity), if requested by the Company to do so, will execute and deliver to the Company, in writing, such other agreements and other documents containing such provisions as the Company may require to assure compliance with applicable securities laws.

(c) The Employee acknowledges and agrees that (i) the certificates representing the Shares, if any, may bear such legend or legends as the Company in its sole discretion deems appropriate in order to assure compliance with applicable securities laws and (ii) the Company may refuse to register transfer of the Shares on the stock transfer records of the Company, and may give related instructions to its transfer agent, if any, to stop registration of such transfer if such proposed transfer, in the opinion of counsel satisfactory to the Company, would constitute a violation of any applicable securities law.

(d) In order to enable the Company to determine when it is entitled to a tax deduction upon the disposition of any Shares issued upon exercise of this Option, for the periods during which such a disposition would entitle the Company to such a deduction (generally, a disposition within two years from the date of grant of the Option or within one year from the date of exercise of the Option will entitle the Company to a deduction), all stock certificates of such Shares shall be held by the Employee in his or her name and not in the name of a broker, nominee or other person or entity, and shall bear a legend reflecting that such Shares were obtained upon exercise of an incentive stock option. The Employee acknowledges that the Company may send a Form W 2, W 2c or substitute therefor, as appropriate, to the Employee with respect to any income recognized by the Employee upon a disposition of the Shares for the periods during which such a disposition would entitle the Company to such a deduction. Nothing in this Section 7(d) shall restrict the Employee from selling, transferring or otherwise disposing of such Shares at any time, but only from holding such Shares in other than his or her own name.

8. Adjustments on Changes in Recapitalization, Reorganization and the Like. Adjustments on changes in recapitalization, reorganization and the like shall be made in accordance with Section 13 of the 2016 Plan, as in effect on the date of this Agreement.

9. No Special Employment Rights. Nothing contained in the 2016 Plan or this Agreement shall be construed or deemed by any person under any circumstances to bind the Company to continue the employment of the Employee for the period within which this Option may be exercised.

10. Rights as a Shareholder. The Employee shall have no rights as a shareholder with respect to any Shares which may be purchased by exercise of this Option unless and until a certificate or certificates representing such Shares are duly issued and delivered to the Employee. Except as otherwise expressly provided in the 2016 Plan, no adjustment shall be made for dividends or other rights for which the record date is prior to the date such stock certificate is issued.

11. Withholding Taxes. Whenever Shares are to be issued upon exercise of this Option, the Company shall have the right to require the Employee to remit to the Company an amount sufficient to satisfy all Federal, foreign, state and local withholding tax requirements prior to issuance of the Shares and the delivery of any certificate or certificates for such Shares. The Employee may satisfy, totally or in part, the Employee's tax obligations pursuant to this Section by electing to withhold or otherwise redeliver Shares acquired upon exercise of this Option.

12. Data Privacy.

(a) To facilitate the administration of the Plan and this Agreement, it will be necessary for the Company (or its payroll administrators) to collect, hold and process certain personal information and other data about Employee and to transfer this data to certain third parties such as brokers with whom Employee may elect to deposit any share capital under the Plan. This personal data may include, but is not limited to, Employee's name, home address and telephone number, date of birth, social security number or other identification number, salary, nationality, job title, Shares held, and details of all Options or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Employee's favor.

(b) **Employee hereby consents to the Company (or its payroll administrators) collecting, holding and processing Employee's personal data and transferring this data to the Company or any other third parties insofar as is reasonably necessary to implement, administer and manage the Plan.**

(c) Employee understands that the this data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in the United States or elsewhere, and that the recipient's country may have different data privacy laws and protections than the United States.

(d) Employee understands that Employee may, at any time, view Employee's personal data, require any necessary corrections to it or withdraw the consents herein in writing by contacting the Company, but acknowledges that without the use of such data it may not be practicable for the Company to administer Employee's involvement in the Plan in a timely fashion or at all and this may be detrimental to Employee.

13. Recoupment. Employee acknowledges that any incentive-based compensation received by Employee from the Company hereunder or otherwise (including any proceeds realized from any exercise of an Option and/or sale of the Shares underlying such Option) shall be subject to recovery by the Company in the circumstances and manner provided in any recoupment policy that may be adopted or implemented by the Company and in effect from time to time on or after the date hereof, and Employee shall effectuate any such recovery at such time and in such manner as the Company may specify. As used herein the "recoupment policy" means and includes any policy of the type contemplated by Section 10D of the Securities Exchange Act of 1934, as amended, any rules or regulations of the Securities and Exchange Commission adopted pursuant thereto, or any related rules or listing standards of any national securities exchange or national securities association applicable to the Company.

14. Qualification under Section 422. It is understood and intended that the Option granted hereunder shall qualify as an "incentive stock option" as defined in Section 422 of the Code. Accordingly, the Employee understands that in order for the Employee to obtain the benefits of an incentive stock option under Section 421 of the Code, no sale or other disposition may be made of any Shares acquired upon exercise of the Option within the one-year period beginning on the day after the day of the transfer of such Shares to him or her, nor within the two-year period beginning on the day after the grant of the Option. **If the Employee intends to dispose or does dispose (whether by sale, gift, transfer or otherwise) of any such Shares within said periods, he or she hereby agrees to notify the Company within thirty (30) days after such disposition.**

15. Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware, without regard to conflict of laws principles.

IN WITNESS WHEREOF, the Company has caused this Agreement to be executed and its corporate seal to be hereto affixed by its officer thereunto duly authorized, and the Employee has hereunto set his or her hand and seal, all as of the day and year first above written.

EMPLOYEE

BRUKER CORPORATION

\_\_\_\_\_

Name: \_\_\_\_\_

Address: \_\_\_\_\_

By: \_\_\_\_\_

Title: \_\_\_\_\_

BRUKER CORPORATION  
FORM OF STOCK OPTION AGREEMENT  
UNDER 2016 INCENTIVE COMPENSATION PLAN  
NON-QUALIFIED STOCK OPTION

AGREEMENT entered into [ ] by and between Bruker Corporation, a Delaware corporation with a principal place of business in Billerica, Massachusetts (the “Company”), and the undersigned (the “Participant”) employee, officer, director, consultant or advisor of the Company or one of its subsidiaries (the Company and its subsidiaries herein together referred to as the “Company”).

1. The Company desires to grant the Participant a non-qualified stock option under the Company’s 2016 Incentive Compensation Plan (the “2016 Plan”) to acquire shares of the Company’s common stock, \$.01 par value per share (the “Shares”).

2. Section 6 of the 2016 Plan provides that each option is to be evidenced by an award agreement, setting forth the terms and conditions of the option.

ACCORDINGLY, in consideration of the premises and of the mutual covenants and agreements contained herein, the Company and the Participant hereby agree as follows:

1. Grant of Option. The Company hereby irrevocably grants under the 2016 Plan and subject to the terms and conditions of the 2016 Plan to the Participant a non-qualified stock option (the “Option”) to purchase all or any part of an aggregate of [ ] Shares on the terms and conditions hereinafter set forth. This option shall not be treated as an incentive stock option under Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”).

2. Purchase Price. The purchase price (“Purchase Price”) for the Shares covered by the Option shall be \$[ ] per Share.

3. Time of Exercise of Option.

(a) The Option shall not be exercisable prior to one (1) year from grant. Thereafter, the Option shall only be exercisable as follows:  
*[modify as appropriate]*

| <u>On or After</u> | <u>Percentage of<br/>Shares Becoming<br/>Available for<br/>Exercise</u> | <u>Cumulative<br/>Percentage<br/>Available</u> |
|--------------------|-------------------------------------------------------------------------|------------------------------------------------|
| 12 months          | 25%                                                                     | 25%                                            |
| 24 months          | 25%                                                                     | 50%                                            |
| 36 months          | 25%                                                                     | 75%                                            |
| 48 months          | 25%                                                                     | 100%                                           |

Exerciseability of the Option upon a Change in Control shall be determined as provided in Section 13 of the 2016 Plan.

4. Term of Options; Exercisability.

(a) Term.

(1) Each Option shall expire not more than ten (10) years from the date of the granting thereof, but shall be subject to earlier termination as herein provided.

(2) Except as otherwise provided in this Section 4, if the Participant ceases to have the same relationship with the Company which was in existence on the date the Option was granted, the Option granted to the Participant hereunder shall terminate on the date that is ninety (90) days after the Participant ceases to have such relationship with the Company, or on the date on which the Option expires by its terms, whichever occurs first, and such Option shall not be exercisable after such date.

(3) If such termination of relationship is because the Participant has become permanently disabled (within the meaning of Section 22(e)(3) of the Code), the Option shall terminate ninety (90) days from the date the Participant ceases to be a Participant, or on the date on which the Option expires by its terms, whichever occurs first.

(4) If the relationship of the Participant with the Company is terminated "for cause", all outstanding and unexercised portions of the Option as of the time the Participant is notified that the Participant's service is terminated "for cause" will immediately be forfeited. For purposes of this Agreement, "cause" shall include (and is not limited to) dishonesty with respect to the Company or any of its affiliates, breach of fiduciary duty, insubordination, substantial malfeasance or non-feasance of duty, unauthorized disclosure of confidential information, material failure or refusal to comply with Company's published policies generally applicable to all employees, and conduct materially harmful to the business of the Company or any of its affiliates. The determination of the Compensation Committee (as defined in the 2016 Plan) as to the existence of "cause" will be conclusive on the Participant and the Company. In addition, "cause" is not limited to events which have occurred prior to the Participant's termination of service, nor is it necessary that the Compensation Committee's finding of "cause" occur prior to termination. If the Compensation Committee determines, subsequent to the Participant's termination of service but prior to the exercise of the Option, or any portion thereof, that either prior or subsequent to the Participant's termination the Participant engaged in conduct which would constitute "cause", then the right to exercise any outstanding unexercised portion of the Option will be immediately forfeited. Notwithstanding the foregoing, any definition in an agreement between the Participant and the Company which (i) contains a conflicting definition of "cause" for termination and (ii) is in effect at the time of such termination shall supersede the definition in this Agreement with respect to the Participant.

(5) In the event of the death of the Participant, the Option granted to the Participant shall terminate ninety (90) days from the date of death, or on the date on which the Option expires by its terms, whichever occurs first.

(b) Exercisability.

(1) If the Participant ceases to have the same relationship with the Company which was in existence on the date the Option was granted, the Option granted to the Participant hereunder shall be exercisable only to the extent that the right to purchase Shares under such Option has accrued and is in effect on the date such Participant ceases to have such relationship with the Company.

(2) No partial exercise may be made for less than one (1) full Share.

(3) In the event of the death of the Participant, the Option granted to such Participant may be exercised by the estate of such Participant, or by any person or persons who acquired the right to exercise such Option by bequest or inheritance or by reason of the death of such Participant.

5. Manner of Exercise of Option.

(a) To the extent that the right to exercise the Option has accrued and is in effect, the Option may be exercised in full or in part by giving written notice to the Company stating the number of Shares exercised and accompanied by payment in full for such Shares. Payment shall be made (a) in cash or by check payable to the order of the Company, (b) at the discretion of the Compensation Committee, and so long as there is no adverse tax or accounting impact to the Company, by delivery of Shares owned by the Participant having a fair market value equal in amount to the exercise price of the Option being exercised and having been held by the Participant for at least six months, (c) at the discretion of the Compensation Committee, by delivery of a properly executed exercise notice to the Company, together with a copy of irrevocable instructions to a broker to deliver promptly to the Company the amount of sale or loan proceeds to pay the exercise price, (d) at the discretion of the Compensation Committee, by a “net exercise” arrangement pursuant to which the Company will reduce the number of Shares issued upon exercise by the largest whole number of Shares with a fair market value that does not exceed the aggregate exercise price, together with cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole Shares, or (e) at the discretion of the Compensation Committee, by any combination of (a), (b), (c) and (d) above. Upon such exercise, delivery of a certificate for paid-up, non-assessable Shares shall be made at the principal office of the Company to the person exercising the Option, not more than thirty (30) days from the date of receipt of the notice by the Company.

(b) The Company shall at all times during the term of the Option reserve and keep available such number of Shares of its common stock as will be sufficient to satisfy the requirements of the Option. The Participant shall not have any of the rights of a stockholder of the Company in respect of the Shares until one or more certificates for such Shares shall be delivered to him or her upon the due exercise of the Option.

6. Non-Transferability. The right of the Participant to exercise the Option shall not be assignable or transferable by the Participant otherwise than by will or the laws of descent and distribution, and the Option may be exercised during the lifetime of the Participant only by him or her. The Option shall be null and void and without effect upon the bankruptcy of the Participant or upon any attempted assignment or transfer, except as hereinabove provided, including without limitation any purported assignment, whether voluntary or by operation of law, pledge, hypothecation or other disposition contrary to the provisions hereof, or levy of execution, attachment, trustee process or similar process, whether legal or equitable, upon the Option.

7. Registration; Compliance with Laws and Regulations; Restrictive Legends.

(a) This Option and the obligation of the Company to sell and deliver Shares hereunder shall be subject in all respects to: (i) all applicable Federal and state laws, rules and regulations; and (ii) any registration, qualification, approvals or other requirements imposed by any government or regulatory agency or body which the Company shall, in its discretion, determine to be necessary or applicable. Moreover, the Option may not be exercised if its exercise, or the receipt of Shares pursuant thereto, would be contrary to applicable law. The Company intends, but is not obligated, to register the Shares for issuance under the Securities Act of 1933, as amended (the “Act”), and to keep such registration effective throughout the period the Option is exercisable.

(b) In the event that for any reason the Shares to be issued upon exercise of the Option shall not be effectively registered under the Act, upon any date on which the Option is exercised in whole or in part, the Participant (or the person permitted to exercise the Option in the event of Participant's death or incapacity) shall execute and deliver to the Company, prior to the delivery of any Shares by the Company pursuant to this Agreement, an agreement (in such form as the Company may specify) in which the Participant (or such person) represents and warrants that such Shares are being acquired for the Participant's own account, for investment only and not with a view to public resale or distribution, and represents and agrees that any subsequent offer for sale or distribution of any kind of such Shares shall be made only pursuant to either (i) a registration statement on an appropriate form under the Act, which registration statement has become effective and is current with regard to the Shares being offered or sold; or (ii) a specific exemption from the registration requirements of the Securities Act. Additionally, the Participant (or the person permitted to exercise the Option in the event of Participant's death or incapacity), if requested by the Company to do so, will execute and deliver to the Company, in writing, such other agreements and other documents containing such provisions as the Company may require to assure compliance with applicable securities laws.

(c) The Participant acknowledges and agrees that (i) the certificates representing the Shares, if any, may bear such legend or legends as the Company in its sole discretion deems appropriate in order to assure compliance with applicable securities laws and (ii) the Company may refuse to register transfer of the Shares on the stock transfer records of the Company, and may give related instructions to its transfer agent, if any, to stop registration of such transfer if such proposed transfer, in the opinion of counsel satisfactory to the Company, would constitute a violation of any applicable securities law.

8. Adjustments on Changes in Recapitalization, Reorganization and the Like. Adjustments on Changes in Recapitalization, Reorganization and the Like shall be made in accordance with Section 13 of the 2016 Plan, as in effect on the date of this Agreement.

9. No Special Rights. Nothing contained in the 2016 Plan or this Agreement shall be construed or deemed by any person under any circumstances to bind the Company to continue the employment or other relationship of the Participant for the period within which this Option may be exercised.

10. Rights as a Shareholder. The Participant shall have no rights as a shareholder with respect to any Shares which may be purchased by exercise of this Option unless and until a certificate or certificates representing such Shares are duly issued and delivered to the Participant. Except as otherwise expressly provided in the 2016 Plan, no adjustment shall be made for dividends or other rights for which the record date is prior to the date such stock certificate is issued.

11. Withholding Taxes. Whenever Shares are to be issued upon exercise of this Option, the Company shall have the right to require the Participant to remit to the Company an amount sufficient to satisfy all Federal, foreign, state and local withholding tax requirements prior to the delivery of any certificate or certificates for such Shares. The Participant may satisfy, totally or in part, the Participant's tax obligations pursuant to this Section by electing to withhold or otherwise redeliver Shares acquired upon exercise of this Option.

12. Data Privacy.

(a) To facilitate the administration of the Plan and this Agreement, it will be necessary for the Company (or its payroll administrators) to collect, hold and process certain personal information and other data about Participant and to transfer this data to certain third parties such as brokers with whom Participant may elect to deposit any share capital under the Plan. This personal data

may include, but is not limited to, Participant's name, home address and telephone number, date of birth, social security number or other identification number, salary, nationality, job title, Shares held, and details of all Options or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant's favor.

(b) **Participant hereby consents to the Company (or its payroll administrators) collecting, holding and processing Participant's personal data and transferring this data to the Company or any other third parties insofar as is reasonably necessary to implement, administer and manage the Plan.**

(c) Participant understands that the this data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in the United States or elsewhere, and that the recipient's country may have different data privacy laws and protections than the United States.

(d) Participant understands that Participant may, at any time, view Participant's personal data, require any necessary corrections to it or withdraw the consents herein in writing by contacting the Company, but acknowledges that without the use of such data it may not be practicable for the Company to administer Participant's involvement in the Plan in a timely fashion or at all and this may be detrimental to Participant.

13. Recoupment. Participant acknowledges that any incentive-based compensation received by Participant from the Company hereunder or otherwise (including any proceeds realized from any exercise of an Option and/or sale of the Shares underlying such Option) shall be subject to recovery by the Company in the circumstances and manner provided in any recoupment policy that may be adopted or implemented by the Company and in effect from time to time on or after the date hereof, and Participant shall effectuate any such recovery at such time and in such manner as the Company may specify. As used herein the “recoupment policy” means and includes any policy of the type contemplated by Section 10D of the Securities Exchange Act of 1934, as amended, any rules or regulations of the Securities and Exchange Commission adopted pursuant thereto, or any related rules or listing standards of any national securities exchange or national securities association applicable to the Company.

14. Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware, without regard to conflict of laws principles.

IN WITNESS WHEREOF, the Company has caused this Agreement to be executed and its corporate seal to be hereto affixed by its officer thereunto duly authorized, and the Participant has hereunto set his or her hand and seal, all as of the day and year first above written.

## PARTICIPANT

BRUKER CORPORATION

\_\_\_\_\_ By: \_\_\_\_\_

Name: \_\_\_\_\_ Title \_\_\_\_\_

Address:

# **FORM OF RESTRICTED STOCK UNIT AWARD AND AGREEMENT**

AGREEMENT entered into this      day of      , 20      by and between Bruker Corporation, a Delaware corporation with a principal place of business in Billerica, Massachusetts (the “Company”), and the undersigned      (the “Participant”) employee, director, consultant or advisor of the Company or one of its subsidiaries (the Company and its subsidiaries herein together referred to as the “Company”).

WITNESSETH:

WHEREAS, the purpose of this Agreement is to evidence and effectuate a Restricted Stock Unit award to the Participant pursuant and subject to the Company’s 2016 Incentive Compensation Plan (the “2016 Plan”); and

WHEREAS, a condition to the grant of the Restricted Stock Units to the Participant is that the Participant execute this Agreement;

NOW, THEREFORE, in consideration of the foregoing, the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

1. Grant. The Company hereby grants to Participant      (      ) Restricted Stock Units (“Units”). Each Unit represents the right to receive one share of the Company’s common stock, par value \$.01 per share (each, a “Share”), subject to the terms and conditions set forth in this Agreement and the 2016 Plan. The Units shall be credited to a bookkeeping account maintained for the Participant on the books and records of the Company and until settled shall continue for all purposes to be part of the general assets of the Company.

2. Forfeiture of Units upon Termination of Employment. Units that do not become vested in accordance with the vesting criteria set forth in Section 3 shall be forfeited to the Company. Accordingly, if the Participant’s employment with the Company terminates for any reason, then all unvested Units shall be automatically forfeited as of the date of termination, and any rights, including, without limitation, any dividend rights, with respect to such forfeited Units will immediately cease.

3. Vesting of Units. So long as the Participant (a) continues to remain as an employee or director of the Company or (b) continues to provide significant services to the Company as a consultant or advisor, the Units will be deemed to become “Vested Units” twenty-five percent (25%) on each of the first four (4) anniversaries of the date of this Agreement.

The foregoing vesting schedule notwithstanding, if the employment, directorship or other business relationship of the Participant with the Company, as applicable, terminates by reason of the Participant’s permanent and total disability (within the meaning of Section 22(e)(3) of the Internal Revenue Code) or death, all Units or portions thereof not yet vested shall become immediately vested. Vesting of the Units upon a Change in Control shall be determined as provided in Section 13 of the 2016 Plan.

4. Timing of Payment of Units. With respect to each portion of the Units that vest, the Company will settle the Vested Units, in the form provided in Section 5 below, within thirty (30) days following the date of vesting. Any amounts payable to Participant under this Agreement are intended to constitute “short-term deferral” described in Treas. Reg. Sec. 1.409A-1(b)(4) so that none of the

payments provided hereunder be deemed a deferral of compensation that is subject to the additional tax imposed under Section 409A of the Internal Revenue Code, and any ambiguities herein shall be interpreted to satisfy the “short-term deferral” exemption.

Notwithstanding the foregoing, neither the Company nor any of its subsidiaries guarantees any tax consequences of Participant’s entitlement to or receipt of payments or other benefits under this Agreement, and the Participant or his or her beneficiaries, heirs or assignees will be solely responsible for payment of any tax obligations incurred in connection with the payments provided under this Agreement.

5. Form of Payment of Units. The Company shall settle a Vested Unit by issuing and delivering to the Participant Shares equal to the number of Units to be so settled. Upon and following the settlement of the Units, the Participant shall be the record owner of the Shares issued in settlement of the Units and shall be entitled to all rights of a stockholder of the Company with respect to voting such Shares and receipt of dividends and distributions on such Shares.

6. Death of Participant. Any distribution or delivery to be made to Participant under this Agreement will, if Participant is then deceased, be made to the administrator or executor of Participant’s estate. Any such administrator or executor must furnish the Company with (a) written notice of his or her status as transferee, and (b) evidence satisfactory to the Company to establish the validity of the transfer and compliance with any applicable laws pertaining to said transfer.

7. Taxes and Withholding. The Company’s obligation to settle Units shall be subject to the Participant’s satisfaction of all applicable Federal, state and local income, excise, employment and any other tax withholding requirements. The Participant may satisfy, totally or in part, the Participant’s tax obligations pursuant to this Section by electing to have Shares withheld from settlement of the award.

8. Rights as Stockholder. The Participant will not have any of the rights or privileges of a stockholder of the Company in respect of the Shares underlying the Units. The Units are unfunded, and the Participant shall have no greater rights in Units than that of an unsecured creditor of the Company.

9. Dividend Equivalents. The Participant’s bookkeeping account shall be credited with an amount equal to the amount of any cash dividends payable with respect to number of Shares with respect to which the Units are determined. Dividend equivalents shall vest and be paid at the same time as the Units with respect to which they are determined.

10. Restrictions on Transfers. Participant shall not sell, assign, transfer, pledge, hypothecate or otherwise dispose of, by operation of law or otherwise (collectively “transfer”), any of the Units, or any interest therein.

11. Specific Enforcement. The Participant expressly acknowledges that the Company may be irreparably damaged if this Agreement is not specifically enforced. Upon a breach or threatened breach of the terms, covenants or conditions of this Agreement by Participant, the Company shall, in addition to all other remedies, be entitled to apply for a temporary or permanent injunction, or a decree for specific performance, in accordance with the provisions hereof.

12. Data Privacy.

(a) To facilitate the administration of the Plan and this Agreement, it will be necessary for the Company (or its payroll administrators) to collect, hold and process certain personal information and other data about Participant and to transfer this data to certain third parties such as

brokers with whom Participant may elect to deposit any share capital under the Plan. This personal data may include, but is not limited to, Participant's name, home address and telephone number, date of birth, social security number or other identification number, salary, nationality, job title, Shares held, and details of all Units or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant's favor.

(b) **Participant hereby consents to the Company (or its payroll administrators) collecting, holding and processing Participant's personal data and transferring this data to the Company or any other third parties insofar as is reasonably necessary to implement, administer and manage the Plan.**

(c) Participant understands that the this data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in the United States or elsewhere, and that the recipient's country may have different data privacy laws and protections than the United States.

(d) Participant understands that Participant may, at any time, view Participant's personal data, require any necessary corrections to it or withdraw the consents herein in writing by contacting the Company, but acknowledges that without the use of such data it may not be practicable for the Company to administer Participant's involvement in the Plan in a timely fashion or at all and this may be detrimental to Participant.

13. Recoupment. Participant acknowledges that any incentive-based compensation received by Participant from the Company hereunder or otherwise (including any proceeds realized from any exercise of an option and/or sale of the Shares underlying such option) shall be subject to recovery by the Company in the circumstances and manner provided in any recoupment policy that may be adopted or implemented by the Company and in effect from time to time on or after the date hereof, and Participant shall effectuate any such recovery at such time and in such manner as the Company may specify. As used herein the "recoupment policy" means and includes any policy of the type contemplated by Section 10D of the Securities Exchange Act of 1934, as amended, any rules or regulations of the Securities and Exchange Commission adopted pursuant thereto, or any related rules or listing standards of any national securities exchange or national securities association applicable to the Company.

14. Notices. Notices given hereunder shall be deemed to have been duly given on the date of personal delivery or on the date of postmark if mailed by certified or registered mail, return receipt requested, to the party being notified at his, her or its address specified on the signature page hereto or such other address as the addressee may subsequently notify the other parties of in writing.

15. Entire Agreement and Amendments. This Agreement constitutes the entire agreement of the parties with respect to the subject matter hereof and neither this Agreement nor any provision hereof may be waived, modified, amended or terminated except by a written agreement signed by the parties hereto. No waiver of any breach or default hereunder shall be considered valid unless in writing, and no such waiver shall be deemed a waiver of any subsequent breach or default of the same or similar nature.

16. Governing Law; Successors and Assigns. This Agreement shall be governed by the internal laws of the State of Delaware without giving effect to the conflicts of laws principles thereof and, except as otherwise provided herein, shall be binding upon the heirs, personal representatives, executors, administrators, successors and assigns of the parties.

17. Severability. If any provision of this Agreement shall be held to be illegal, invalid or unenforceable, such illegality, invalidity or unenforceability shall attach only to such provision and shall not in any manner affect or render illegal, invalid or unenforceable any other provision of this Agreement, and this Agreement shall be carried out as if any such illegal, invalid or unenforceable provision were not contained herein.

18. Captions. Captions are for convenience only and are not deemed to be part of this Agreement.

19. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, this Agreement has been executed as of the date and year first above written.

PARTICIPANT

BRUKER CORPORATION

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Address: \_\_\_\_\_

By: \_\_\_\_\_  
Title: \_\_\_\_\_

## CERTIFICATION

I, Frank H. Laukien, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Bruker Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
  - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 5, 2016

By: /s/ FRANK H. LAUKIEN, PH.D.

Frank H. Laukien, Ph.D.

*President, Chief Executive Officer and Chairman*

*(Principal Executive Officer)*

---

## CERTIFICATION

I, Anthony L. Mattacchione, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Bruker Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
  - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 5, 2016

By: /s/ ANTHONY L. MATTACCHIONE

Anthony L. Mattacchione  
Chief Financial Officer and Senior Vice President  
(Principal Financial Officer)

---

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT  
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Bruker Corporation (the "Company") on Form 10-Q for the three and six months ended June 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), each of the undersigned, Frank H. Laukien, President, Chief Executive Officer and Chairman of the Board of Directors of the Company, and Anthony L. Mattacchione, Chief Financial Officer and Senior Vice President of the Company, certifies, pursuant to 18 U.S.C. section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

- (1) The Report fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 5, 2016

By: /s/ FRANK H. LAUKIEN, PH.D.  
Frank H. Laukien, Ph.D.  
*President, Chief Executive Officer and Chairman*  
*(Principal Executive Officer)*

Date: August 5, 2016

By: /s/ ANTHONY L. MATTACCHIONE  
Anthony L. Mattacchione  
*Chief Financial Officer and Senior Vice President*  
*(Principal Financial Officer)*

---